|
January | February | March | April | May | June | July | August | September | October | November | December |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Atugen AG (Germany) | Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Collaboration to validate high-priority disease-associated genetic targets of interest to OGS | OGS will provide novel high-priority drug targets to Atugen to enable validation in specific cell lines and in animal models of human diseases; Atugen will optimize its GeneBloc and cellular delivery technologies to knock down the expression of these targets |
| AxCell Biosciences (subsidiary of Cytogen Corp.; CYTO) | Pluvita Corp. | Binding term sheet agreement for a pilot program to research protein interactions | The goals will be to identify the full-length peptides that bind Pluvita's compounds, and identify apparent consensus sequences and analyze the representation of those sequences within the human proteome |
| Bioject Medical Technologies Inc. (BJCT) | Amgen Inc. (AMGN) | Agreement that broadens Amgen's potential use of Bioject's needle-free injection system and includes product licensing and commercial supply terms | Bioject will provide Amgen with an exclusive license for use of a modified version of the Bioject B2000 needle-free injection system for certain undisclosed therapeutics; Bioject will receive an up-front payment of $1M, as well as milestone and other payments |
| Cambridge Antibody Technology Group plc (UK; LSE:CAT; CATG) | Amrad Corp. Ltd. (Australia; ASX:AML) | Product development collaboration focused on the joint discovery and development of human antibody-based therapeutics that neutralize the receptor for granulocyte macrophage-colony stimulating factor | The companies will fund all development jointly through Phase II; CAT then has responsibility for further development and commercialization; Amrad has the option to receive milestone and royalty payments or to participate jointly in further development and commercialization |
| Caprion Pharmaceuticals Inc. (Canada) | Ortho-Clinical Diagnostics Inc. (a Johnson & Johnson company) | Exclusive licensing agreement to develop a human blood test for variant Creutzfeldt-Jacob disease | The agreement is an extension of the initial research collaboration in which Ortho exercised an option to license Caprion's prion technologies; Ortho obtained worldwide exclusive rights in marketing and distribution for human in vitro diagnostic applications and will fund all development activities and regulatory expenses |
| Cellomics Inc. | Norak Biosciences Inc. | Cross-license agreement granting Norak nonexclusive rights to Cellomics' intellectual property for high-content screening | Cellomics gains rights to Norak's intellectual property for Transfluor to facilitate the development and commercialization of software |
| ChemBridge Laboratories LLC | Tularik Inc. (TLRK) | Two-year agreement to apply CRL's chemistry platform to Tularik's research for the discovery of novel therapeutics | CRL will receive a technology access fee and success-based milestones |
| Chiron Corp. (CHIR) | Inhale Therapeutic Systems Inc. (INHL) | Collaboration to produce an inhaled, dry powder tobramycin therapy for the treatment of Pseudomonas aeruginosa lung infections | Inhale will develop the formulation, and be responsible for clinical and commercial manufacturing of the drug formulation and device combination; Chiron will commercialize the resulting product; Inhale will receive research and development funding, milestone payments and royalties |
| ConjuChem Inc. (Canada; TSE:CJC) | Trimeris Inc. (TRMS) | Agreement for the exclusive right to negotiate for a worldwide license to ConjuChem's Drug Affinity Complex technology to create long-lasting HIV compounds | Trimeris paid an undisclosed up-front fee for the exclusive negotiating rights |
| Cureon A/S (Denmark) | Oxagen Ltd. (UK) | Collaboration under which Cureon will validate a specified number of gene targets for Oxagen | Cureon will perform the work with its SmART-Validation target validation service based on locked nucleic acid technology |
| Cytos Biotechnology AG (Switzerland) | Millennium Pharmaceuticals Inc. (MLNM) | Agreement for two deorphaning projects in biotherapeutics to search for new disease-relevant targets and drug candidates | Millennium will acquire the rights to screen for small-molecule compounds or other drug entities directed against the targets discovered; Millennium also gains the rights to develop and commercialize protein therapeutics resulting from the collaboration; Cytos will receive up-front payment and research milestones, and potentially commercialization milestones and license fees, as well as royalties |
| DiaDexus Inc. | Quest Diagnostics Inc. (NYSE:DGX) | Licensing agreement for a genomics-based diagnostic test for the noninvasive detection of colorectal cancer | Quest obtained exclusive rights to develop and commercialize the colorectal cancer test in its laboratories in the U.S. and certain international territories; DiaDexus will receive an up-front licensing fee and royalties on sales and retains rights to develop a test for certain markets |
| Eukarion Inc. | Proteome Systems Inc. (Australia) | Collaborative program on the proteomics of aging | The program is focused on mitochondrial oxidative stress and the role of mitochondrial dysfunction in aging and degenerative neurological disease; Eukarion will provide synthetic pharmacological compounds |
| ExonHit Therapeutics (France) | bioMerieux-Pierre Fabre (France) | Five-year alliance to develop ExonHit's cancer diagnostic, Proof-Hit, for breast and colon cancer | ExonHit will leverage its core Datas technology to define genetic signatures that will be compiled on its analytical macroarrays |
| Galapagos Genomics NV (Belgium) | Euroscreen SA (Belgium) | Collaboration to identify activators of G protein-coupled receptors, for which no ligands are known | Galapagos will provide an arrayed collection of secreted proteins and peptides from human cells infected with the Galapagos PhenoSelect library |
| GeneFormatics Inc. | IBM Corp. (NYSE:IBM) | Agreement in which IBM becomes GeneFormatics' preferred information technology and services partner | IBM will provide a range of hardware and software products and services to support GeneFormatics' work in discovering the functions and structures of thousands of proteins; IBM also is participating in GeneFormatics' third round of equity financing |
| GeneProt Inc. | Waters Corp. (NYSE:WAT) | Partnership to expand GeneProt's proteomics capabilities through its new industrial-scale proteomics facility in the U.S. | Waters, through its subsidiary, Micromass UK Ltd., will purchase equity securities of GeneProt with a maximum value of $10M; GeneProt will purchase about $20M of mass spectrometry equipment from Micromass |
| Genicon Sciences Corp. | BD Biosciences Clontech (unit of Becton, Dickinson and Co.) | Agreement to design resonance light scattering signal generation and detection technology for use with BD Biosciences Clontech's line of BD Atlas Microarrays | The companies hope to provide scientists with a means to detect differential gene expression as compared to commonly used fluorescent-based detection methods |
| Graffinity Pharmaceutical Design GmbH (Germany) | Structural GenomiX | Collaboration aimed at creating an approach for more rapid lead discovery | Graffinity will screen several targets, supplied by SGX, with its library of small molecular fragments; Graffinity will synthesize selected fragments and SGX will co-crystallize a combination of selected fragments with the targets and provide precise images of the interaction topology and binding modes |
| Immune Network Ltd. (Canada; OTC BB:IMMKF; CDNX:IMM) | InNexus Corp. | Sublicensing option agreement for the application of SuperAntibody technology to Immune Network's monoclonal antibodies hNM01 and IF7 | InNexus will pay Immune Network $1M in the form of its common shares issued annually in three installments, in addition to a single-digit royalty |
| Incyte Genomics Inc. (INCY) | Cambridge Antibody Technology Group plc (UK; LSE:CAT; CATG) | Agreement that gives CAT access to the Incyte LifeSeq Gold database and options for product development rights | CAT will receive access to high-quality, sequence-verified human cDNA clones and rights to use this information for therapeutic antibody product development; CAT will pay a license fee, plus milestones and royalties for products developed |
| Isis Pharmaceuticals Inc. (ISIP) | Chiron Corp. (CHIR) | Target validation collaboration in which Chiron gains access to Isis' applications of antisense technology and a license to specific patents within Isis' functional genomics suite of patents | Chiron will use the technology as a tool for gene functionalization and target validation; it also can use the Ribonuclease H mechanism of action for its in-house antisense-based functional genomics program |
| Isis Pharmaceuticals Inc. (ISIP) | Amgen Inc. (AMGN) | Three-year agreement for Isis to use its technology to discover drugs from Amgen targets | Isis will use its second-generation chemistry, 2'-0-methoxyethyl, to inhibit several gene targets; Amgen has the right to develop and commercialize any resulting antisense drugs; Isis will get an up-front fee, funding for research, milestones and royalties |
| MDS Pharma Services (Canada; unit of MDS Inc.; NYSE:MDZ; TSE:MDS) | Iconix Pharmaceuticals Inc. | Agreement to advance a novel chemogenomics information system for drug discovery and development | MDS Pharma will help develop the system, DrugMatrix, and also will make an equity investment in Iconix, and commit other funds and technology to the development of DrugMatrix |
| MethylGene Inc. (Canada) | ChemBridge Research Laboratories LLC | Research and license agreement to design small-molecule inhibitors | MethylGene gets a license to any compounds developed; CRL will get access fees, milestone payments and royalties |
| Millennium Pharmaceuticals Inc. (MLNM) | Xenova Group plc (UK; XNVA) | License agreement to develop and commercialize three of Xenova Group's potential cancer drugs | The $31.5M deal aims to develop three compounds that have a mechanism of action for the treatment of solid tumors; the compounds are XR11576, XR5944 and XR11612 |
| Molecular Mining Corp. | NextGen Sciences Ltd. (UK) | Agreement in the area of protein biochips | The agreement adapts the companies' respective products for optimal integration and productivity and co-promotes their products |
| Orchid BioSciences Inc. (ORCH) | Quest Diagnostics Inc. (NYSE:DGX) | Nonexclusive license covering the commercial use of Orchid's SNP-IT technology for gene-based diagnostic testing services using SNAPshot reagent kits marketed by Applied Biosystems Group | Orchid received an up-front payment and will earn royalties on all diagnostic services performed by Quest using Orchid technology |
| Pharmacopeia Inc. (PCOP) | Locomogene Inc. | Research collaboration in the osteoarthritis/rheumatoid arthritis area | Pharmacopeia will provide assay development expertise, a compound sample collection and ultra-high-throughput screening technology to identify lead compounds for a Locomogene target |
| Plexxikon Inc. | Scynexis Chemistry & Automation Inc. | Agreement under which Plexxikon will access Scynexis' MedChem-Factory technology as part of a ramp-up of Plexxikon's chemistry programs | The agreement provides Plexxikon with dedicated chemistry processes using technology from chemists experienced in automation and high-throughput discovery chemistry |
| Protein Design Labs Inc. (PDLI) | Celltech Group plc (UK; NYSE:CLL; LSE:CCH) | Nonexclusive license for humanized antibodies against tumor necrosis factor-alpha | The license was granted under the terms of an agreement announced in January 2000 covering certain intellectual property in the field of humanized antibodies, and triggers the payment of an additional license fee to PDL |
| Quintiles Transnational Corp. (QTRN) | Discovery Laboratories Inc. (DSCO) | Agreement to sell and market Discovery's Surfaxin | Quintiles' investment group, PharmaBio Development Inc., will purchase $3M of Discovery common equity and make available a line of credit of $8.5M to $10M; PharmaBio will fund the sales and marketing costs for Surfaxin for seven years, and may make certain milestone payments, in return for a commission on net sales over a 10-year period |
| Ribozyme Pharmaceuticals Inc. (RZYM) | Geron Corp. (GERN) | Collaboration to accelerate the process development for Geron's lead telomerase inhibitor, GRN163 | RPI will use its expertise in nucleic acid technology and will assist Geron in the scale-up and optimization of the manufacturing process; the companies also will collaborate to explore the potential for a ribozyme-based telomerase inhibitor, which Geron will have the first right to commercialize |
| Sicor Inc. (SCRI) | EPIC Therapeutics Inc. | Licensing and development agreement for the depot formulation (LeuProMaxx) of leuprolide acetate formulated to be clinically equivalent to Lupron Depot | Sicor and EPIC intend to develop additional compounds over the contract term to further capitalize on EPIC's technology |
| SkyePharma plc (UK; SKYE; LSE:SKP) | Astralis Ltd. (OTC BB:ASTR) | Agreements concerning the formulation and development of Astralis' injectable vaccine therapy, Psoraxine, to treat psoriasis | SkyePharma will receive a $5M license fee for access to DepoFoam and other relevant drug delivery technologies; SkyePharma also will provide all development, manufacturing, preclinical and clinical development services for second-generation Psoraxine, up to the completion of Phase II, and it will make an equity investment in Astralis of up to $20M |
| Variagenics Inc. (VGNX) | GeneMatrix Inc. (Korea) | Research and development collaboration to develop molecular diagnostic products for predicting response to leading drugs in the treatment of colon and gastric cancer | The companies will collaborate on pharmacogenomic research and clinical development of targeted therapeutics |
| Vical Inc. (VICL) | CytRx Corp. (CYTR) | Exclusive, worldwide license agreement granting Vical rights to CytRx's TranzFect poloxamer technology to enhance viral or nonviral delivery of polynucleotides in all human and animal health applications, except four infectious disease vaccine targets and prostate-specific membrane antigen | Vical will make an up-front payment and CytRx will have the opportunity for milestones and royalties |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| AlphaGene Inc. | Celera Genomics Group (NYSE:CRA) | Agreement to allow Celera to distribute AlphaGene's collection of human full-length genes | Celera will be responsible for marketing these services through its Celera Discovery System subscription database; AlphaGene will be responsible for isolating known clones through their AlphaGene Clone Database, and will fully sequence and manufacture the clones |
| Antisense Therapeutics Ltd. (unit of Circadian Technologies Ltd.; Australia) | Isis Pharmaceuticals Inc. (ISIP) | Collaboration to discover and develop antisense drugs | Isis will be handed 14% of the issued capital of Antisense plus another 20M options (equivalent to about 23% of Antisense, if exercised) and will be entitled to royalties from drug discoveries; Antisense gains the right to commercialize ISIS 107248 (ATL 1102), a candidate for multiple sclerosis |
| Archemix Inc. | Gilead Sciences Inc. (GILD) | Licensing agreement for Gilead's aptamer technology | Archemix will pay $17.5M for the license |
| AxCell Biosciences Corp. (a subsidiary of Cytogen Corp.; CYTO) and InforMax Inc. (INMX) | Pluvita Corp. | Three-year nonexclusive agreement to use AxCell's ProChart database in drug discovery | Financial terms were not disclosed |
| BioSante Pharmaceuticals Inc. (BTPH) | Corixa Corp. (CRXA) | Licensing agreement for BioSante's Bio-Vant vaccine adjuvant on a nonexclusive basis | Corixa will use the adjuvant in several potential vaccines it will develop; Corixa will pay BioSante milestone payments and royalty payments on potential sales |
| Celera Genomics Group (NYSE:CRA) | Immusol Inc. | Multiyear subscription agreement for the Celera Discovery System | Financial terms were not disclosed |
| Celera Genomics Group (NYSE:CRA) | Compaq Canada Corp. (Canada) | Exclusive agreement in which Compaq Canada will be the preferred distributor of access to the Celera Discovery System | Compaq Canada will distribute the access to the non-profit research community in Canada |
| Cerep SA (France) | Sepracor Inc. (SEPR) | Five-year research and development collaboration that gives Sepracor access to Cerep's BioPrint database | Cerep will receive annual fees, as well as milestone payments and royalties |
| Cetek Corp. | Lexicon Genetics Inc. (LEXG) | Agreement to develop assays and perform high-throughput screens against several novel in vivo validated targets | The companies will screen against targets for the discovery of lead compounds from Lexicon's compound libraries |
| DiaDexus Inc. | Quest Diagnostics Inc. (NYSE:DGX) | Licensing agreement for Cathepsin K genomics-based diagnostic blood test for the detection and monitoring of osteoporosis | Quest exercised its option under a previous agreement and has obtained exclusive rights to develop and commercialize the test in the U.S. and certain international territories; DiaDexus will receive an up-front licensing fee and royalties on future sales |
| DoubleTwist Inc. | Neurogen Corp. (NRGN) and Evotec NeuroSciences GmbH (Germany) | Subscription agreement to DoubleTwist's GenomeZone service for genomic research | The service will give the companies online access to the entire DoubleTwist Annotated Human Genome Database; financial terms were not disclosed |
| Dyax Corp. (DYAX) | Licentia Ltd. (Finland) | Exclusive rights agreement to develop antibody drugs and diagnostic products aimed at an undisclosed angiogenesis target | No further details were disclosed |
| Epimmune Inc. (EPMN) | Bavarian Nordic A/S (Denmark; CSE:BAVA) | Collaboration agreement to combine technologies to develop vaccines for the treatment or prevention of HIV infection | The companies will combine Epimmune's technology in the fields of T-cell epitope identification and vaccine design with Bavarian's vaccine delivery technology, Modified Vaccinia Ankara |
| ExonHit Therapeutics (France) | Allergan Inc. | Access agreement for ExonHit's Signal-Hit technology to identify new molecular targets for Allergan's drug discovery program | Companies will study tissue obtained from Allergan's disease model system following treatment with drug candidates; Allergan will have the option to take a commercial license for therapeutic and diagnostic rights to selected clones; Allergan will pay technology access fees, and also may make milestone and royalty payments |
| Flamel Technologies SA (France; FLMLY) | An undisclosed biopharmaceutical company | Agreement to investigate the application of Flamel's Medusa controlled-release protein and peptide delivery technology to an existing and specific class of proteins | The work will be fully funded by Flamel's partner |
| GeneLink Inc. (OTC BB:GNLK) | Orchid BioSciences Inc. (ORCH) | Commercial single nucleotide polymorphism genotyping service agreement | Orchid will perform high-throughput SNP genotyping of samples provided by GeneLink |
| Gene Logic Inc. (GLGC) | BioCarta Inc. | Exclusive commercial-use licensing agreement to BioCarta's collection of signal transduction pathways for use in visualizing protein interactions linked to Gene Logic's GeneExpress suite of information products | Gene Logic obtains multiyear access to BioCarta's pathways, as well as exclusive rights to use these data in the context of a commercially available database product |
| Genzyme Molecular Oncology (GZMO) | Kirin Brewery Co. Ltd. | Multimillion-dollar collaboration to develop and commercialize fully human monoclonal antibodies as therapies in anti-angiogenesis and vascular targeted cancer drug delivery | Terms include a $2M up-front fee for Genzyme plus two years of full research funding; Genzyme also will receive milestone payments |
| Gilead Sciences Inc. (GILD) | OSI Pharmaceuticals Inc. (OSIP) | Agreement for Gilead to sell its oncology pipeline to OSI for up to $200M | OSI is paying $130M in cash and $40M in stock for all rights to Gilead's cancer pipeline plus the Boulder, Colo., operations; OSI will pay Gilead up to $30M more when milestones are reached in development of NX211 |
| GPC Biotech AG (Germany; FSE:GPC) | ICOS Corp. (ICOS) | Development and manufacturing agreement for GPC's anti-MHC class II antibodies | The agreement includes a nonexclusive license to ICOS's mammalian cell expression technology; ICOS will conduct development, scale-up and GMP manufacturing in its cell culture manufacturing facility; GPC retains all rights to develop and commercialize the product |
| GPC Biotech AG (Germany; FSE:GPC) | Altana AG (Germany) | Agreements related to the establishment of a genomics research center in Waltham, Mass. | GPC will provide Altana with licenses, capacities for collaboration and facilities related to the new research center, in return for up to $70M of a potential $120M investment |
| ICOS Corp. (ICOS) | Afferon Corp. | Licensing agreement for RTX to treat urological disorders | ICOS gains worldwide rights to RTX; Afferon receives an up-front payment, milestones and royalties on any approved products; ICOS will pay for development and commercialization of RTX and any analogues |
| Immusol Inc. | NeoGenesis Pharmaceuticals Inc. | Collaboration to discover small-molecule drug candidates to treat HIV | NeoGenesis will apply its drug discovery technologies to Immusol's biologically validated cellular drug targets; no money is being exchanged |
| Incyte Genomics Inc. (INCY) | Dr. Reddy's Laboratories Ltd. (India; NYSE:RDY) and Reddy US Therapeutics Inc. | Agreement allowing the companies access to LifeSeq Gold and ZooSeq | Financial terms were not disclosed |
| Inpharmatica Ltd. (UK) | Celera Genomics Group (NYSE:CRA) | Joint program to develop and commercialize a new version of Inpharmatica's Biopendium target and drug discovery platform | The new product is to be called Celera Edition Biopendium; it is expected to be launched early next year and will apply Inpharmatica's protein structure/function prediction technology to Celera's mammalian sequences and other public domain sequences |
| Isis Pharmaceuticals Inc. (ISIP) | OncoGenex | Drug development collaboration agreement to codevelop OGX-011 | Isis will be responsible for conducting preclinical studies and will manufacture OGX-011; OncoGenex will perform Phase I/II trials of OGX-011 |
| LION bioscience AG (Germany; LEON) | IBM Corp. | Agreement to work together on harnessing the data from human genome studies so it can be used for more effective and faster drug discovery and development | IBM and LION will jointly market enterprise-wide drug discovery solutions |
| LION bioscience AG (Germany; LEON) | ACE BioSciences A/S (Denmark) | Collaboration agreement in the field of proteomics | LION granted several user licenses for its software products to ACE, which will apply these modules to conduct its own proteomics research in the field of pathogenic microorganisms |
| Maxygen Inc. (MAXY) | Novozymes A/S (Denmark; CSE:KFX) | Agreement in which Novozymes will advance into development two additional enzyme product candidates that were developed using Maxygen's MolecularBreeding directed molecular evolution technologies | Maxygen will receive royalty payments on the sales of any products in the expanded industrial enzyme market areas; Maxygen will have co-exclusive rights to use the technologies for certain new industrial enzyme markets |
| Medarex Inc. (MEDX) | Ambit Biosciences Corp. | Multiyear collaboration to use Medarex's UltiMAb Human Antibody Development System and Ambit's ProteomeScan screening technology to develop and commercialize monoclonal antibody therapeutic products | The companies will share equally the costs and revenues of any products; Medarex made a $1M equity investment in Ambit |
| Medarex Inc. (MEDX) | m-Phasys GmbH (Germany) | Collaboration for the development and commercialization of fully human antibody therapeutics to G protein-coupled receptors | Medarex plans to generate fully human antibodies to GPCRs produced using m-Phasys' M-Fold refolding technology; the companies will jointly develop any therapeutics generated, and will share costs and commercialization rights |
| Millennium Pharmaceuticals Inc. (MLNM) | XOMA Ltd. (XOMA) | Agreement to further develop a pair of Millennium's biotherapeutic agents, CAB-2 and LDP-01, for certain vascular inflammation indications | XOMA is responsible for development costs through the completion of Phase II trials; it also will make initial payments to Millennium, as well as after reaching certain clinical milestones; Millennium retains commercialization rights; it also committed to purchase at XOMA's option up to $50M worth of XOMA stock over the next three years |
| Millennium Pharmaceuticals Inc. (MLNM) | Targeted Diagnostics and Therapeutics Inc. | Licensing agreement for TDT's intellectual property surrounding guanylyl cyclase C, and its related ST ligand, for use in colorectal cancer therapeutics | Millennium gained an exclusive worldwide license and will pay milestone fees and potential royalties to TDT; Millennium also will make an initial equity investment in TDT |
| Myriad Genetics Inc. (MYGN) | Biosearch Italia S.p.A. (Italy; Nuovo Mercato:BIO) | Three-year collaboration to discover therapeutic compounds using naturally occurring products | Myriad will select two or three drug targets each year from heart disease to cancer; it will develop the targets and high-throughput assays to screen against Biosearch's library |
| Orchid BioSciences Inc. (ORCH) | Invitrogen Corp. (IVGN) | Agreement under which Invitrogen acquired exclusive worldwide rights to offer genotyping products to the research market using Orchid's single nucleotide polymorphism scoring technology in a 96-well format | Invitrogen can develop, manufacture and market genotyping kits using Orchid's SNP scoring technology and offer customers access to Orchid's SNP primer design algorithms; Invitrogen will pay Orchid a royalty on kit sales |
| Oxigene Inc. (OXGN) | Active Biotech AB (Sweden; SSE:ACTI) | Agreement to out-license, on a nonexclusive basis, Oxigene's benzamide technology platform for all indications | Active gains the right to further develop and commercialize positive leads for all indications; Active will bear all costs for the development and commercialization efforts and will share with Oxigene any milestone and royalty payments resulting from the program |
| Paradigm Genetics Inc. (PDGM) | StemCo BioMedical Inc. | Research collaboration for the biochemical profiling of adult human stem cells | Paradigm will use its metabolomics technology platform, MetaVantage, to elucidate the biochemical profiles of adult stem cells, and will use the profiles to identify all of the small molecules present |
| Paradigm Genetics Inc. (PDGM) | Thermo Electron Corp. (NYSE:TMO) | Strategic alliance to design and develop the next generation of chromatography/mass spectrometry systems for use in the field of metabolomics | Paradigm will provide technical and implementation consulting services to Thermo Electron's business, Thermo Finnigan, and have exclusive precommercial access to the new instruments and systems |
| Prescient NeuroPharma Inc. (Canada; CDNX:PRE) | Access Oncology Inc. | Licensing agreement for Prescient's anticancer compound, anhydrovinblastine | The agreement could be worth more than $25M; it calls for Prescient to receive up-front payments of $1.25M, milestone payments of $17.5M, and royalties on net sales; Access will be responsible for all development and marketing costs |
| Proteome Sciences Ltd. (Australia) | IBM Life Sciences | Alliance in which IBM will provide the information technology backbone for Proteome Systems' commercial offerings, including its platform for proteome analysis, ProteomIQ | The companies will collaborate on research initiatives and marketing programs; IBM will supply hardware, software and services for Proteome's in-house research and databases |
| Psychiatric Genomics Inc. | ReNeuron Holdings plc (UK) | Agreement to use fetal stem cells for growing “mini-brains“ in order to screen compounds that target neurological disorders | PGI gets a worldwide exclusive license to use specific cell lines within the field of the agreement in exchange for an initial cash payment and warrants, which become exercisable upon the achievement of milestones |
| Pyrosequencing AB (Sweden; SSE:PYRO) | Genomics Collaborative Inc. | Partnership to accelerate the development of cardiovascular diagnostic and therapeutic products | Pyrosequencing's genotyping technology and intellectual property and GCI's clinical samples and database will be applied to the discovery and validation of genetic markers for cardiovascular disease |
| Rinat Neuroscience Corp. | Genentech Inc. (NYSE:DNA) | Licensing agreement for Genentech's genomic and bioinformatics technologies and the right to use secreted proteins, receptors and antibodies for research in the neurology field | The agreement led to the company's $17.5M private financing |
| Rosetta Biosoftware (unit of Rosetta Inpharmatics Inc.) | COR Therapeutics Inc. (CORR) | Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System | Financial terms were not disclosed |
| Symyx Technologies Inc. (SMMX) | Celanese Ltd. (subsidiary of Celanese AG; NYSE:CZ; Germany) | Extension to a collaboration for the discovery of catalysts for commodity chemicals | Celanese will continue to fund Symyx's discovery efforts and will have exclusive rights to commercialize materials discovered within the field of the collaboration; Symyx will receive royalties on the sale of any products commercialized |
| Syngenta Biotechnology Inc. | Egea Biosciences Inc. | Collaboration to design and engineer plants that will resist pests through the incorporation of genes for naturally occurring molecules | Egea will use its gene synthesis technology to engineer extremely long pieces of DNA that encode a series of genes that when introduced into a plant will produce organic molecules |
| Synt:em (France) | IBM Corp. | Agreement in the field of virtual ultra-high-throughput screening | Synt:em will combine the IBM xSeries supercomputer cluster with its own computational predictive platform for rational drug design, Acti:map, to accelerate and optimize drug discovery |
| Syrrx Inc. | Onyx Pharmaceuticals Inc. (ONXX) | Agreement in which Syrrx acquires certain assets from the small-molecule discovery program of Onyx | Syrrx will receive certain drug targets, including related reagents and assays, as well as compound libraries and licenses to certain intellectual property assets and technologies; Onyx will receive equity in Syrrx, future milestone payments and royalties on resulting products |
| Theratechnologies Inc. (Canada; TSE:TH) | Bachem Ltd. (Switzerland) | Agreement for the development of a large-scale manufacturing process | The agreement would allow Theratechnologies' subsidiary Peptix to develop the active ingredient ThGRF at a competitive cost |
| Third Wave Technologies Inc. (TWTI) | Riken (The Institute of Physical and Chemical Research; Japan) | Worldwide exclusive licensing agreement for drug metabolizing enzymes | The license excludes Japan; the deal involves an up-front payment to Riken and an agreement for future royalties |
| Transtech Pharma Inc. | Novo Nordisk A/S (Denmark) | Three-year research collaboration that will focus on the discovery and development of new targets in diabetes | The agreement involves a Transtech program in diabetes that Novo Nordisk is supporting in return for exclusive worldwide rights to certain products; Transtech will receive an up-front payment, three years of research support and potential milestones and royalties |
| Valentis Inc. (VLTS) | Genetronics Biomedical Corp. (AMEX:GEB) | Nonexclusive license to in vivo electroporation technology from Genetronics for use in the development of certain Genemedicine products | Financial terms were not disclosed |
| Variagenics Inc. (VGNX) | Nanogen Inc. (NGEN) | Worldwide licensing agreement for patent rights to Variagenics' methylenetetrahydrofolate reductase | Variagenics granted Nanogen nonexclusive rights to commercialize home-brew and analyte-specific reagent tests aimed at the assessment of thrombo-embolic disease risk; Variagenics retains the rights to develop diagnostic tests and all other pharmacogenomic applications |
| Vasogen Inc. (Canada; TSE:VAS; AMEX:MEW) | Quest Diagnostics Inc. | Strategic alliance to jointly commercialize Vasogen's immune modulation therapy in the U.S. | Quest will make a US$7.5M equity investment in Vasogen; the alliance covers all indications |
| X-Mine Inc. | BioCardia Inc. | Licensing and collaboration agreement for X-Mine's data mining and knowledge discovery platform, X-Miner | Terms involve early access to X-Mine's molecular pattern recognition and computational systems |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Aclara BioSciences Inc. (ACLA) | Third Wave Technologies Inc. (TWTI) | Collaboration for the development and commercialization of multiplexed gene expression research products | The collaboration couples the high-multiplexing capabilities of Aclara's eTag sequence-labeling technology with Third Wave's Invader platform |
| Advanced Tissue Sciences Inc. (ATIS) | Medtronic Inc. (NYSE:MDT) | Collaboration to explore how the companies' technologies can work together | A Medtronic affiliate purchased $20M of ATS's common stock as part of the partnership; ATS and Medtronic will test ATS's technology in cardiovascular, neurological, endocrinological and spinal areas; Medtronic receives a right of first refusal for development and to pursue programs |
| Affymetrix Inc. (AFFX) | Millennium Pharmaceuticals Inc. (MLNM) | Four-year research and development agreement to develop a new generation of Affymetrix's GeneChip | Affymetrix is giving Millennium preferred access and pricing to the gene expression platform, in return for a volume commitment to GeneChip |
| Agenix Ltd. (Australia) | Immunomedics Inc. (IMMU) | Nonexclusive license agreement that gives Agenix access to Immunomedics' technology | The technology covers the labeling of antibodies with the radioisotope technetium |
| Agilent Technologies Inc. (NYSE:A) | Paradigm Genetics Inc. (PDGM) | Multiyear collaboration to commercialize the first whole Arabidopsis thaliana genome microarray for use in gene expression studies | Paradigm will receive volume discounts on microarrays and royalties from co-developed products |
| Alexion Pharmaceuticals Inc. (ALXN) | Novagen Inc. | Agreement for exclusive worldwide commercial rights to technology that allows the rapid discovery of antibody drug candidates | Alexion's license covers human therapeutic antibodies; financial terms were not disclosed |
| Alkermes Inc. (ALKS) | Bioject Medical Technologies Inc. (BJCT) | Development agreement to advance Alkermes' compounds | The companies will develop up to three drugs using Bioject's Iject, along with other needle-free systems; Alkermes will provide monthly payments to Bioject, adding cash as milestones are met; a commercial supply agreement for Iject is included in the deal |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Atrix Laboratories Inc. (ATRX) | Licensing agreement providing the rights to oral low-dose interferon-alpha for the treatment of Behcet's disease and oral papillomavirus warts in HIV-positive patients | Atrix paid $485,000 for licensing orphan drug designations and clinical studies; Atrix will fund the research, and Amarillo will receive payments for specific clinical and regulatory milestones and will receive royalties |
| Argenta Discovery Ltd. (UK) | De Novo Pharmaceuticals Ltd. (UK) | Collaboration directed toward certain De Novo drug discovery targets | Argenta will provide De Novo with synthetic chemistry and screening services for the generation and testing of low-molecular-weight, drug-like compounds |
| Artificial Life Inc. (OTC BB:ALIF) | BeFutur Biotechnologies SA (Switzerland) | Partnership agreement | The companies will cooperate on stem cell research, simulation and analysis of cell growth patterns, regenerative medicine and product and vaccine development |
| Athersys Inc. | 3-Dimensional Pharmaceuticals Inc. (DDDP) | Collaboration to discover, develop and commercialize small-molecule drugs by screening against targets derived from the G protein-coupled receptor family of proteins | Athersys will supply the drug targets; any small-molecule drug candidates identified will be co-developed and co-commercialized on a 50-50 basis |
| Azign Bioscience A/S (Denmark) | Nordic Bioscience A/S (Denmark) | Agreement to identify new drugs for treatment of diseases of bones and joints, particularly osteoporosis | Azign will receive milestone payments and royalties following identification of new products through its gene expression analysis technology |
| Berna Biotech Ltd. (Switzerland) | Bachem Ltd. (Switzerland) | Joint venture agreement to develop therapeutic and prophylactic peptide vaccines | The companies are investing CHF20M (US$12.13M) to fund the joint venture, which will focus on melanoma, malaria, hepatitis C and Alzheimer's disease |
| BioMarin Pharmaceutical Inc. (BMRN) | IBEX Technologies Inc. (Canada; TSE:IBT) | Agreement for IBEX's pharmaceutical assets | BioMarin is paying $10.5M ($8.5M in BioMarin stock) for IBEX's assets, including Neutralase, and has promised another $9.5M based on product approvals |
| Bruker Daltonics Inc. (BDAL) | Biacore International AB (Sweden) | Agreement to attempt to integrate Biacore's surface plasmon resonance technology with Bruker's mass spectrometry capabilities | The companies expect to have products ready and begin sales sometime in 2002 |
| Celera Genomics Group (NYSE:CRA) | Sagres Discovery | Multiyear subscription agreement to allow Sagres scientists to access the Celera Discovery System | Financial terms were not disclosed |
| Celera Genomics Group (NYSE:CRA) | Structural GenomiX Inc. | Multiyear marketing and distribution partnership for ModBase, SGX's database containing more than 310,000 computationally modeled protein structures | Celera will offer ModBase as part of its Celera Discovery System |
| Cellectis SA (France) | genOway SA (France) | Worldwide nonexclusive licensing agreement for the patent EP419621 | The patent covers the use of homologous recombination for the development of cellular and animal models |
| Cel-Sci Corp. (AMEX:CVM) | Biomedex Inc. | Joint development agreement to develop and manufacture rapid anthrax human screening and rapid anthrax human diagnostic tests | Biomedex will be responsible for securing both the necessary funding for the project and access to the reagents and materials required for the development projects |
| ConjuChem Inc. (Canada; TSE:CJC) | Heska Corp. (HSKA) | Research collaboration to develop a DAC compound for an undisclosed veterinary application | Heska will conduct compound testing and optimization studies for a 12-month period; Heska will have the option to negotiate a license and development agreement; ConjuChem received an undisclosed up-front payment |
| Deltagen Inc. (DGEN) | Hyseq Inc. (HYSQ) | Agreement in which Deltagen will research and develop about 200 novel secreted proteins provided by Hyseq | Hyseq will pay Deltagen about $10M in research and development payments over two years; Deltagen will receive about $10M in equity proceeds from the sale of 1.51M shares of common stock to George Rathmann, chairman of Hyseq; companies will share some costs and split equally any targets developed |
| Dendreon Corp. (DNDN) | Geron Corp. (GERN) | Licensing agreement for the use of human telomerase as an antigen in Dendreon's therapeutic cancer vaccines | Dendreon has three cancer vaccines in clinical trials, including Provenge to treat prostate cancer |
| DoubleTwist Inc. | GPC Biotech AG (Germany) | Licensing agreement for DoubleTwist's Prophecy database and tools suite | Prophecy provides GPC access to annotated public genome data |
| Drug Royalty Corp. Inc. (Canada; TSE:DRI) | Celgene Corp. (CELG) | Agreement giving Drug Royalty a new royalty interest in worldwide sales | Drug Royalty acquired the interest for $4.7M; the term of the agreement is tied to issued U.S. patents, the latest of which will expire no later than 2015 |
| Entelos Inc. | Zen-Bio Inc. | Research collaboration to study human fat cells in an effort toward developing new obesity therapeutics | The agreement may entail co-marketing, co-publication and the co-delivery of validated drug targets or candidates to pharmaceutical companies; the companies would evenly split research funding, milestones and royalties |
| Epigenomics AG (Germany) | MethylGene Inc. (Canada) | Collaboration to investigate gene methylation changes of patients enrolled in Phase II trials of MG98 | MG98 is a second-generation antisense oligonucleotide that inhibits DNA methyltransferase mRNA; financial details were not disclosed |
| Exelixis Inc. (EXEL) | Scios Inc. (SCIO) | Four-year collaboration to develop a variety of lead compound structures for both companies | Exelixis will receive a fee per compound in addition to an up-front payment |
| Genaco Biomedical Products Inc. | Luminex Corp. (LMNX) | Multiyear agreement permitting Genaco to develop and commercialize reagent kits based on the Luminex LabMAP platform for the Chinese in vitro diagnostics market | The LabMAP platform will be marketed in China under the brand name Gena MASA (Multi-Analyte Suspension Array) |
| GeneFormatics Inc. | Bruker BioSpin Corp., Bruker AXS Inc. and Bruker Daltonics Inc. (BDAL) | Partnership to develop next-generation technologies for the analysis of 3-dimensional protein structures and the supply of various research infrastructure systems | The Bruker companies will make equity investments in GeneFormatics' Series C round of financing, and GeneFormatics will make equity cross investments in Bruker AXS and Bruker Daltonics |
| Genmab A/S (Denmark) | Immunex Corp. (IMNX) | Collaboration agreement to discover and develop an antibody against an Immunex cancer target to treat lymphoma | Genmab will be responsible for developing the antibody, HuMax-Lymphoma, through Phase II trials; Immunex will have an exclusive option to take responsibility for completing clinical development and would pay Genmab a license fee, milestones and share profits if it is commercialized |
| Genmab A/S (Denmark) | Scancell Ltd. (UK) | Collaboration to develop fully human antibodies to cancer targets identified by Scancell | The first antibody product will target Lewis (y/b), a target overexpressed on breast, lung, colon and ovarian cancers; the companies will share development costs and commercialization rights |
| Genome Therapeutics Corp. (GENE) | Biosearch Italia S.p.A. | Agreement for the U.S. and Canadian rights to ramoplanin, which is in Phase III for prevention of bloodstream infections | Genome Therapeutics will pay an initial $2M plus milestone payments up to $8M in cash and notes convertible into its stock; Genome Therapeutics also is under obligation to purchase bulk material from Biosearch, to fund the clinical trials and to pay a royalty on product sales |
| Genomics Collaborative Inc. | Cypress Bioscience Inc. (CYPB) | Agreement to provide DNA banking services | Genomics will provide Cypress with clinical research support enabling the collection, processing and storage of DNA, cerebral spinal fluid and lymphocyte transformation |
| Gilead Sciences Inc. (GILD) | Archemix Corp. | Out-licensing agreement for Gilead's intellectual property rights under the SELEX (Systemic Evolution of Ligands Through Exponential Enrichment) process patent estate | Gilead will receive $17.5M in cash, as well as warrants in Archemix; the agreement provides exclusive rights to the SELEX process, including therapeutic and other commercial applications |
| Imaging Research Inc. (Canada) | Genicon Sciences Corp. | Software licensing, promotion and distribution agreement for Imaging Research's ArrayVision microarray analysis software and Genicon's resonance light scattering signal detection technology | Imaging Research will supply ArrayVision to Genicon for promotion and commercialization in concert with resonance light scattering technology |
| Immunomedics Inc. (IMMU) | AGEN Biomedical Ltd. (Australia) | Licensing agreement for its method of directly labeling antibodies with technetium-99m (Tc-99m) | AGEN gains nonexclusive worldwide use with its clot-imaging agent under development |
| Incyte Genomics Inc. (INCY) | Genentech Inc. (NYSE:DNA) | Licensing agreement for patent rights covering therapeutic antibodies to four proteins discovered by Incyte | Incyte is entitled to receive milestones for clinical development; it also may receive royalties on any commercialized products |
| Incyte Genomics Inc. (INCY) | Epoch Biosciences Inc. (EBIO) | Alliance designed to leverage the intellectual property assets of both companies | Agreement gives Epoch access to LifeSeq Gold and ZooSeq to allow development of oligonucleotide probes based on Incyte's gene content; Epoch will be a preferred provider of the probes; it also includes a supply of Epoch Eclipse Probe Systems for Incyte internal development purposes |
| Invitrogen Corp. (IVGN) | Gryphon Sciences | Nonexclusive sublicense for Native Chemical Ligation patents for the synthesis of proteins using chemical means | Invitrogen plans to use the patents to develop products to facilitate molecular biology research in proteomics |
| Isogenica Ltd. (UK) | Affitech A/S (Norway) | Collaboration and licensing agreement for the development and commercialization of Isogenica's Covalent Display Technology | Affitech will use CDT to generate high-affinity human antibodies; Isogenica will get license fees and royalties, as well as scientific input for its research and development program |
| Medarex Inc. (MEDX) | Incyte Genomics Inc. (INCY) | Collaboration to develop antibodies using Medarex's UltiMAb Human Antibody Development System | Cancer and other life-threatening and debilitating diseases will be targeted; each company equally assumes responsibility for costs associated with development, and they will share commercialization expenses and profits |
| MediChem Life Sciences Inc. (MCLS) | Cephalon Inc. | Service agreement for protein crystallography of an undisclosed target | MediChem will receive technology access fees, full-time employment funding and milestone payments |
| Metabasis Therapeutics Inc. | ICN Pharmaceuticals Inc. (NYSE:ICN) | Licensing agreement for Metabasis' hepatitis B compound | Metabasis was paid initial fees and could be paid milestones in the $20M to $30M range, as well as royalties; ICN will pay all development costs |
| Microbiotix Inc. | Phytobiotech Inc. (Canada) | Research and screening collaboration to identify and develop antibiotic agents that inhibit bacterial DNA replication | The new antibiotics will be used to address the increasing worldwide problem of antibiotic-resistant bacterial infections |
| Microscience Ltd. | Anadis Ltd. (Australia) | Licensing agreement for technology for the high-speed identification of virulence genes in pathogenic bacteria for use in a Helicobacter pylori vaccine program | Anadis is paying US$100,000 up front, and will split equally any revenues with Microscience |
| Millennium Pharmaceuticals Inc. (MLNM) | ILEX Oncology Inc. (ILXO) | Agreement to dissolve the 50-50 joint venture, Millennium & ILEX Partners LP | ILEX gains Millennium's 33% ownership of Campath for about $140M; the joint venture will end at the end of the year when Millennium will receive $20M in cash and will be eligible for a $40M yearly payment over three years, if Campath's U.S. sales reach $15M annually; Millennium also will receive a royalty beginning in 2005 if Campath sales reach a certain level |
| Modex Therapeutics Ltd. (Switzerland; SWX:MDXN) | Eukarion Inc. | Exclusive license for worldwide rights to a small molecule for the prevention and treatment of radiation-induced skin damage | Modex will develop the compound into a topical protective treatment for radiation patients; it plans to begin a Phase I trial next year |
| Morphochem AG (Germany) | Automated Cell Inc. | Agreement to identify, optimize and produce small-molecule drug candidates through a joint-development program | Candidates will be produced through a combination of Automated Cell's Protein Function Discovery platform and Morphochem's chemical genomics program; companies have begun work in oncology and will share ownership of any candidates |
| Myriad Genetics Inc. (MYGN) | Pharmacia Corp. (NYSE:PHA) | Collaboration on a research project in pharmacogenomics aimed at identifying genetic differences among individuals in the general population | Myriad will screen populations of individuals for polymorphisms, or differences in the particular genes that are the targets of drugs |
| NetGenics Inc. | Paradigm Genetics Inc. (PDGM) | Agreement for a multiseat DiscoveryCenter license | Paradigm is one of the first customers of the NetGenics integration software |
| Neurochem Inc. (Canada; TSE:NRM) | Select Therapeutics Inc. (AMEX:XZL) | Collaboration aimed at the discovery of a vaccine intended to prevent the development and progression of Alzheimer's disease | Neurochem will provide Alzheimer's disease antigens from its proprietary library; Select will use its Verovax technology to target antigens isolated by Neurochem directly to dendritic cells |
| November AG (Germany; Neuer Markt:NBX) | MediRox AB (Sweden) | Agreement granting exclusive rights to MediRox for further development and marketing of a system called novi quick | November will get a percentage of any sales, and expects to receive a significant share of MediRox |
| Orchid BioSciences Inc. (ORCH) | Ellipsis Biotherapeutics Corp. (Canada) | SNP and pharmacogenomics collaboration | Orchid will work with Ellipsis to conduct high-throughput SNP genotyping and to construct high-density chromosome maps using samples provided by Ellipsis; the focus initially will be on inflammatory bowel disease; Orchid has rights for diagnostic applications |
| Oxagen Ltd. (UK) | Isis Innovation (technology transfer arm of Oxford University) | Agreement for exclusive rights to a series of patents | The patents cover gene polymorphisms with potential association to Oxagen's work in complex inflammatory and autoimmune disease areas; Isis received an up-front payment and may receive further payments and royalties |
| Pharmacopeia Inc. (PCOP) | Ester Neurosciences Ltd. | Agreement to focus on neurological diseases involving the neuropathological upregulation of Ester's proprietary target, a variant of acetylcholinesterase | Pharmacopeia will receive research funding, and also may receive additional payments for identifying active compounds and achieving other milestones; it also will receive royalties |
| Progenics Pharmaceuticals Inc. (PGNX) | Formatech Inc. | Collaboration to develop improved product formulations for PRO 542, a drug in Phase II testing for HIV | Terms were not disclosed |
| Qiagen NV (the Netherlands; QGENF) | Kreatech biotechnology BV (the Netherlands) | Agreement to a deal granting Qiagen an exclusive license to Kreatech's Universal Linkage System labeling technologies and products | The products will be used in combination with Qiagen's resonance light scattering products licensed from Genicon Biosciences; Qiagen also acquired nonexclusive rights to develop and sell ULS products for labeling and detecting nucleic acids as well as proteins in microarray applications |
| Rigel Pharmaceuticals Inc. (RIGL) | Evotec OAI AG (Germany; Neuer Markt:EVT) | Medicinal chemistry agreement for the optimization of small molecules focused on inhibitors of ubiquitin ligases | Rigel will provide funding for Evotec for services, and Evotec may receive milestone payments |
| SangStat Inc. (SANG) | Endocyte Inc. | Agreement that grants Endocyte a nonexclusive, worldwide license to commercialize vitamin-based treatments using Sangstat's complexine technology | Endocyte has the right to sublicense the technology; financial terms include license fees and royalties on sales |
| Seattle Genetics Inc. (SGEN) | Proacta Therapeutics (New Zealand) | Agreement to license certain cell-killing drugs | Seattle Genetics will evaluate the synthetic drugs as product candidates; it will have exclusive development, manufacturing and worldwide commercialization rights to any products using the drugs |
| Symyx Technologies Inc. (SMMX) | Prolinx Inc. | Nonexclusive license agreement under which Prolinx intends to commercialize products incorporating a polymer developed by Symyx | Prolinx intends to launch substrates and protein arrays using the Symyx material before the end of the year, and to start receiving royalties from the sale of these products in early 2002 |
| Synt:em (France) | Boston Life Sciences Inc. (BLSI) | Research collaboration that will use Synt:em's peptide vector technology, Pep:trans, to improve delivery of a novel central nervous system diagnostic into the brain | The companies will fund certain percentages of costs, and will derive a defined split of potential revenue and royalties from marketed products; Synt:em will be paid for access to Pep:trans |
| Viaken Systems Inc. | Sun Microsystems Inc. (SUNW) | Agreement to introduce a new suite of data and process integration platforms | Viaken is developing a suite of discovery platforms to help eliminate discovery bottlenecks, accelerate product development, decrease research and development costs and reduce development time |
| Vical Inc. (VICL) | Ichor Medical Systems Inc. | Agreement to develop products based on Vical's naked DNA technology | Ichor will deliver the products using its electroporation systems |
| VitaResc AG (Germany) | Evotec OAI AG (Germany) | Extended collaboration related to development of VitaResc's antithrombotic drug VTR-RI | The initial agreement was signed in the summer of 2000; expansion includes the scaling up of production of the drug, supplying clinical-grade material for trials |
| Xenogen Corp. (XGEN) | Incyte Genomics Inc. (INCY) | Licensing and asset acquisition agreement for an Incyte lab and animal facility based in St. Louis, and a nonexclusive license to a package of intellectual property | Xenogen acquired the license and assets in a cash transaction |
| Xenon Genetics Inc. | QuantaNova Canada Ltd. (Canada) | Agreement in which Xenon acquired QuantaNova's lipid metabolism drug discovery program | Xenon paid cash for the program |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| 3-Dimensional Pharmaceuticals Inc. (DDDP) | Cyprotex Ltd. (UK) | Collaboration for the use of Cyprotex's computerized methods for the prediction of human pharmacokinetics | The collaboration will focus on the application of Cyprotex's ADME prediction methods along with 3DP's Discover Works small-molecule drug discovery process to improve preclinical drug optimization |
| 4SC AG (Germany) | Axxima Pharmaceuticals AG (Germany) | Research collaboration to identify small-molecule kinase inhibitors for the treatment of human cytomegalovirus infections | Axxima will develop and commercialize any resulting anti-infective HCMV kinase inhibitors; 4SC will receive milestone and royalty payments |
| Agilent Technologies Inc. (NYSE:A) | Incyte Genomics Inc. (INCY) | Expanded licensing agreement to further Agilent's development and commercialization of gene expression microarrays using Incyte's gene patent portfolio and genomic databases | Incyte will receive additional license fees as well as royalties on sales of Agilent microarrays |
| AlleCure Corp. | BD Biosciences (division of Becton, Dickinson and Co.; NYSE:BDX) | Research collaboration to develop assays in support of AlleCure's AlleVax treatments for allergies and various autoimmune diseases | The work will focus on the development of laboratory tests that may be used for allergy diagnosis, confirmation of vaccine efficacy and continued patient monitoring before, during and after immunotherapy |
| Amersham Pharmacia Biotech | Aurora Biosciences Corp. (subsidiary of Vertex Pharmaceuticals Inc.; VRTX) | Agreement to commercialize their combined Green Fluorescent Protein technology, which is used to accelerate drug discovery and development | The agreement will allow both companies to broaden access to GFP technology |
| Aquasearch Inc. (OTC BB:AQSE) | Ancile Pharmaceuticals Inc. | Intent for an agreement to work on the development of microalgae-based botanical drugs | The alliance will combine Aquasearch's pipeline of microalgae products and Ancile's drug development knowledge and technology platform |
| Array BioPharma Inc. (ARRY) | Vertex Pharmaceuticals Inc. (VRTX) | Agreement to discover and develop small-molecule drugs for two targets in the phosphatase protein family area | Array will be responsible for initial drug discovery, while Vertex can conduct its own research in the area and will be responsible for clinical development and commercialization; Array will receive an up-front fee and research funding for three years, as well as milestone payments |
| atugen AG (Germany) | Arena Pharmaceuticals Inc. (ARNA) | Agreement to evaluate the use of atugen's technology for Arena's research and development in the area of G protein-coupled receptors | atugen plans to knock down the expression of central nervous system gene targets provided by Arena, which will use the GeneBloc antisense molecules to evaluate gene function in CNS in vivo models |
| Biacore International AB (Sweden; BCOR) | Axiom Biotechnologies Inc. | Agreement to give Biacore an exclusive license to all of Axiom's fluorescent cell-based assay technology with the exception of flow cytometry-based applications | Biacore's goal is to drive the commercialization of this technology |
| Bio-Reference Laboratories Inc. (BRLI) | Visible Genetics Inc. (Canada; VGIN) | Agreement to offer VGI's TruGene HIV-1 Genotyping Test to Bio-Reference customers treating patients with HIV infections | The companies will co-market and support the product in New York, New Jersey and greater Philadelphia, and provide programs for physicians and patient education |
| BTG plc (UK; LSE:BGC) | Genentech Inc. (NYSE:DNA) | Exclusive rights agreement to develop an atrial natriuretic factor peptide technology | The technology has been shown to have therapeutic potential in treating acute congestive heart failure, acute renal failure and renal hypertension |
| Corvas International Inc. | Dyax Corp. | Collaboration to develop novel cancer therapeutics focused on serine protease inhibitors | The companies will assume joint development of any product candidates that may be identified and will share commercialization rights and profits from any marketed products |
| Devgen NV (Belgium) | Metabolex Inc. | Research collaboration in which each company will employ its respective technology platforms to evaluate the other's compounds, in hopes of more rapidly assessing potential therapeutic utility of the compounds in diabetes | Devgen will analyze Metabolex compounds and Metabolex will analyze Devgen compounds; each party will retain ownership rights to its compounds |
| Discovery Partners International Inc. (DPII) | The Genetics Co. Inc. | Collaborative research agreement to identify drug leads for the treatment of colon cancer | The goal is to test thousands of chemical substances in a high-throughput screen for the ability to block the activity of a critical protein and to inhibit uncontrolled cell division |
| Endovasc Ltd. (OTC BB:ENDV) | CytoGenix Inc. | Cooperative research and development agreement in which Endovasc will use its liposome technology to encapsulate the CytoGenix single-strand DNA expression systems, producing unmodified strands of ssDNA for therapeutic applications | The goal is to protect the ssDNA from destruction by exo- and endo-nucleases found on the skin and in the bloodstream |
| Epicyte Pharmaceutical Inc. and Dow Chemical Co. | Centocor Inc. | Agreement to evaluate production of a therapeutic human monoclonal antibody in plants | The agreement involves Epicyte's Plantibody technology; Centocor has the option to enter into an exclusive commercial supply agreement for a variety of clinical indications |
| Epimmune Inc. (EPMN) | Anosys Inc. | Nonexclusive license to certain cancer antigens for use in Anosys' cancer therapy program | License, which is worldwide, except for Japan, covers certain patented and nonpatented rights to Epimmune's universal breast, colon, lung and prostate epitope packages for use in ex vivo cancer therapy; agreement includes an up-front license fee, milestones and royalties |
| GeneData AG (Switzerland) | diaDexus Inc. | License agreement for the GeneData Expressionist microarray data analysis system | The system is designed to rapidly screen through functional genomics data in order to determine genes that are the basis for disease |
| Genencor International Inc. (GCOR) | Integrated Genomics Inc. | Licensing agreement for three microbial genome sequencing technologies | Genencor will have access to Integrated Genomics' Aspergillus niger genome sequence data, the ERGO bioinformatics suite and Genome Explorer |
| Genomics Collaborative Inc. | Specialty Laboratories Inc. (NYSE:SP) | Research collaboration to study the clinical significance of new laboratory markers of disease | The study will combine GCI's high-throughput genetic analysis tools and specimen resources with Specialty's test development and commercialization expertise |
| Hybrigen Inc. | Bionomics Ltd. (Australia) | Letter of intent to negotiate the terms of a collaboration to discover drug targets in breast cancer | The program will be based on genes identified and patented by Bionomics, focused initially on the TSG18 and BNO1 genes |
| ImmuneTech Inc. | Luminex Corp. (LMNX) | Partnership permitting ImmuneTech to develop and commercialize a line of allergy tests based on Luminex's Multi-Analyte Profiling technology | ImmuneTech gains access to LabMAP to perform allergy testing services and to produce allergy testing panels |
| Incyte Genomics Inc. (INCY) | Galapagos Genomics NV (Belgium) | Extended functional genomics collaboration based on the LifeSeq collection | Galapagos will construct a custom adenoviral library harboring genes relevant to Incyte's in-house drug target discovery and validation efforts |
| InterMune Inc. (ITMN) | Maxygen Inc. (MAXY) | Collaboration for the development of the next generation of Actimmune | InterMune will take into the clinic the potential products created by Maxygen during the next two or three years; InterMune will pay for development and keeps worldwide commercialization rights, giving Maxygen up-front license fees, research funding and milestone payments that could exceed $60M, as well as royalties |
| Jomed NV (Switzerland; SWX:JOM) | OxiGene Inc. (OXGN) | Collaboration to research restenosis inhibitors, integrating Jomed's stent technology with OxiGene's platform of vascular targeting agents | Jomed will perform proof-of concept studies using OxiGene's vascular targeting agents on drug-eluting stents |
| MediChem LifeSciences Inc. (MCLS) | Rigel Pharmaceuticals Inc. (RIGL) | Two-year collaboration in structural proteomics for drug development, initially focused on ubiquitin ligases | MediChem will express, purify and co-crystallize Rigel protein complexes, and then determine their structures, as well as co-crystallize several Rigel small-molecule drug leads with protein complexes; Rigel will pay MediChem for research, as well as milestones |
| MorphoSys AG (Germany; Neuer Markt:MOR) | Oridis Biomed Forschungs-und Entwicklungs GmbH (Austria) | Agreement to provide MorphoSys with access to one of the world's largest tissue banks | MorphoSys will apply its HuCal technology to make antibodies to candidate targets, which Oridis Biomed will use to perform high-throughput protein expression analysis on a range of human tissue; Oridis Biomed will receive a license to the HuCal technology and will have access to certain antibodies |
| NeoGenesis Drug Discovery Inc. | Tularik Inc. (TLRK) | Agreement in which Tularik will provide disease targets to NeoGenesis, which will screen for small-molecule drug candidates of those targets | Tularik is providing research funding; NeoGenesis may receive milestones and royalty payments on products developed by Tularik |
| Ocean Pharmaceuticals Inc. | Diabact AB (Sweden) | Licensing agreement for U.S. rights to a new sublingual/bioadhesive technology | Terms were not disclosed |
| Plexus Vaccine Inc. | Molsoft LLC | Licensing agreement to discover and commercialize new interventional strategies for global infectious diseases, for drug-resistant microbes and for chronic diseases associated with cryptic pathogens | Using Molsoft software, Plexus is developing Virtual Epitope databases of molecular targets for in silico design of structural mimics that can be readily synthesized, tested and formulated as vaccines |
| Proteome Systems (Australia) | Protagen AG (Germany) | Collaboration involving the exchange of analysis of post-translational modifications of proteins | Proteome will have access to Protagen's methodology and technology for the purpose of analysis of protein phosphorylation and Protagen will have access to Proteome System's methodology and technology for the analysis of protein glycosylation |
| Sequitur Inc. | Discovery Genomics | Agreement focused on screening antisense compounds to elucidate gene function in zebra fish | Sequitur will retain rights to discoveries of gene function in the areas of bone, hematopoiesis and obesity; Discovery Genomics will retain rights relating to the balance of vertebrate disease studies in the zebra fish model |
| Sicor Inc. (SCRI) | Biomedical Frontiers Inc. | Licensing agreement for a novel iron chelator drug candidate for potential use in treating iron overload in patients with transfusion-dependent sickle cell anemia and thalassemia | Terms of the agreement were not disclosed |
| Structural Bioinformatics Inc. | ChemNavigator Inc. | Agreement to combine SBI's technologies in 3-dimensional computational proteomics with ChemNavigator's technologies in chemistry | The companies will share any generated revenues |
| Structural GenomiX Inc. | Compaq Computer Corp. | Agreement to develop SGX's structural informatics systems | SGX will purchase a complete Compaq technology solution, which will assist SGX and its partners in target identification and validation, lead selection and screening, and optimization of compounds for binding and selectivity |
| Tangerine Technologies Inc. | ImClone Systems Inc. (IMCL) | Agreement to license Tangerine's OligoBuyer | ImClone will use OligoBuyer to specify, order and track its purchases of custom-configured strands of DNA and RNA |
| Thales Industrial Services (France) | Proteus International (France) | Collaborative agreement to develop a novel system using genetic technologies to detect and monitor biological terrorism | The agreement has been entered into within the framework of a public tender from the French Direction General des Armees of the Department of Defense of the French Republic |
| The PSMA Development Co. LLC (joint venture between Progenics Pharmaceuticals Inc., PGNX; and Cytogen Corp., CYTO) | AlphaVax Human Vaccines Inc. | Exclusive worldwide licensing agreement for the AlphaVax Replicon Vector system | The system will be used to create a therapeutic prostate cancer vaccine using PSMA's prostate-specific cancer antigen |
| TranXenoGen Inc. | Amgen Inc. (AMGN) | Collaboration to produce a proprietary monoclonal antibody | This is TranXenoGen's fourth such deal; the company specializes in the production of pharmaceutical proteins in hen eggs |
| Tranzyme Inc. | Active Pass Pharmaceuticals Inc. (Canada) | Collaboration in the areas of gene expression and drug discovery | The alliance will use Tranzyme's TexT in support of the ABC transporter chemogenomic program at Active Pass, which will provide multiple sets of ABC transporter gene sequences; Tranzyme will deliver these genes into mammalian cells and express and purify the proteins |
| ViroLogic Inc. | Triangle Pharmaceuticals Inc. | Agreement to assist in clinical evaluation of new anti-HIV agents being developed by Triangle | Triangle will use ViroLogic's PhenoSense HIV phenotypic drug resistance assay to evaluate the effectiveness of its investigational nucleoside reverse transcriptase inhibitors |
| Xenon Genetics Inc. (Canada) | Discovery Partners International Inc. (DPII) | Agreement for drug discovery | Discovery Partners will provide high-throughput screening, chemistry and informatics services to Xenon's drug discovery program |
| XOMA Ltd. (XOMA) | Dompe SpA (Italy) | Nonexclusive licensing agreement for the use of XOMA's patented technology for biopharmaceutical production | Dompe is using the technology in developing a fully human Fab for radioimmunotherapy of ovarian carcinoma |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Abgenix Inc. (ABGX) | Agensys Inc. | Research collaboration option and license agreement under which the companies will develop fully human monoclonal antibody therapies against selected cancer antigen targets | Agensys has option rights to exclusive product licenses for up to 25 targets during the five-year collaboration; Abgenix will receive research license payments and could receive additional fees and milestone payments, as well as royalties; Agensys will be responsible for product development, manufacturing and commercialization |
| Affymetrix Inc. (AFFX) | Orchid BioSciences Inc. (ORCH) | Agreements to expand their existing collaboration to combine Orchid's primer extension technology with the Affymetrix GeneChip GenFlex Tag Array in Orchid's SNPcode genotyping kits | Orchid obtained nonexclusive, royalty-bearing rights to use Affymetrix's universal oligonucleotide sequences for primer extension applications; Affymetrix granted Orchid a nonexclusive license to make and sell products incorporating its universal Tag sequences |
| Albany Molecular Research Inc. (AMRI) | Cubist Pharmaceuticals Inc. (CBST) | Research and licensing agreement for the discovery of a new class of anti-infective drugs designed to break through the resistance of stubborn microorganisms | AMRI is entitled to milestone fees and royalties; Cubist obtains worldwide rights to develop and market resulting drugs |
| Amsterdam Molecular Therapeutics BV (the Netherlands) | Xenon Genetics Inc. (Canada) | Exclusive sublicense and research agreement in a deal that gives AMT access to technology and intellectual property relating to lipoprotein lipase LPL | AMT and Xenon will join forces in a preclinical research program for LPL gene therapy; AMT will be responsible for further development and commercialization |
| Antisoma plc (UK) | Cancer Research Ventures Ltd. (UK) | Licensing agreement for DMXAA, a vascular targeting agent | Antisoma in-licensed the product, which has completed two Phase I studies and was seen to control the growth of tumors in animal models |
| Arena Pharmaceuticals Inc. (ARNA) | TaiGen Biotechnology Co. (Taiwan) | Licensing agreement for G protein-coupled receptor research | Arena gets about $7M up front |
| Atrix Laboratories Inc. (ATRX) | Human Genome Sciences Inc. (HGSI) | Agreement to develop a sustained-released formulation of an HGS protein with Atrix's Atrigel Depot drug delivery system | HGS will provide funding and the work will be performed at Atrix's facility |
| BioReliance Corp. (BREL) | MediGene Inc. (Germany; Neuer Markt:MDG) | Agreement to produce clinical supplies of herpes simplex virus-derived G207 and NV1020 | MediGene will develop both products; BioReliance will provide manufacturing and testing services for the products and production will occur in BioReliance's facility in Rockville |
| Biovation Ltd. (UK) | Micromet AG (Germany) | Research agreement for Biovation to apply its DeImmunisation technology to therapeutic proteins designed by Micromet | Biovation will earn research revenues, and will receive license fees and potential milestone payments |
| Celera Genomics Group (NYSE:CRA) | SomaLogic | Multiyear collaboration giving Celera access to aptamers and aptamer arrays developed through SomaLogic's Selex process | Agreement also provides SomaLogic access to sequencing and proteins for developing aptamers |
| Cellectis SA (France) | Zentaris AG (Germany) | Worldwide license agreement that gives Zentaris rights to patents covering single long terminal repeats, a technology for gene transfer | Zentaris will use the technology to improve its existing gene therapies for cancer |
| Cepheid Inc. (CPHD) | Environmental Technologies Group Inc. | Collaboration to develop biological-agent detection systems for military and other domestic preparedness applications | The companies will develop and design the systems based on Cepheid's technologies for the capture, purification, amplification and detection of DNA |
| Chiron Corp. (CHIR) | Medivir AB (Sweden) | Collaboration centered on hepatitis C virus infections in which compound libraries from Medivir will be screened in Chiron's HCV assays | Chiron may choose to extend support beyond the initial one-year agreement; it also has an option to secure exclusive worldwide commercialization rights and could pay license and milestone fees totaling more than $10M, as well as royalties |
| CollaGenex Pharmaceuticals Inc. (CGPI) | Atrix Laboratories Inc. (ATRX) | Exclusive licensing and marketing agreement for Atrix's dental products, Atridox, Atrisorb-FreeFlow and Atrisorb, in the U.S. | Atrix will manufacture the products at an agreed transfer price and will receive royalties; CollaGenex paid a $1M up-front licensing fee; Atrix purchased 330,556 newly issued shares of CollaGenex stock |
| CV Therapeutics Inc. (CVTX) | Incyte Genomics Inc. (INCY) | Expanded 1998 research agreement to focus on identifying genes involved in the development of atherosclerosis and coronary artery disease | CVT will develop biological models to study genes implicated in cardiovascular disease, and will supply mRNA from these models to Incyte, which will analyze them |
| DNAPrint Genomics Inc. (OTC BB:DNAP) | Pharsight Corp. (PHST) | Contract to allow DNAPrint to accelerate its pharmacogenomics research and product development | Pharsight will supply DNAPrint with clinically phenotyped specimens from patients taking a variety of medications |
| DoubleTwist Inc. | GeneProt Inc. | Licensing agreement for DoubleTwist's Prophecy suite for its proteomics research | GeneProt also licensed the commercial version of the GeneCards database, which is distributed by DoubleTwist |
| Entelos Inc. | Compaq Computer Corp. (NYSE:CPQ) | Three-year agreement that will provide technology to support new drug development and disease research | Entelos will use Compaq's AlphaServer running the Tru64 UNIX and Compaq ProLiant servers running Linux as the computational platforms for its high-throughput PhysioLab systems |
| Epimmune Inc. (EPMN) | Biosite Inc. (BSTE) | Nonexclusive license agreement for the Padre R technology | Biosite intends to develop these antibodies for use in its products and for use in collaborations |
| Galapagos Genomics NV (the Netherlands) | Vertex Pharmaceuticals Inc. (VRTX) | Research collaboration in which Galapagos will provide custom-based recombinant adenoviruses for protein targets of interest | Vertex will use the adenoviruses to characterize protein activity within targeted biological pathways |
| Genencor International Inc. (GCOR) | Phogen Inc. (joint venture company of Xenova Group plc; UK; XNVA) | Licensing agreement for the VP22 technology | Genencor will use the technology in its vaccines programs; Phogen will receive up-front license fees, research and development funding and annual license maintenance fees, as well as milestone payments; the deal is potentially worth more than $21M |
| Genomics Collaborative Inc. | ActivX Bioscience Inc. | Partnership to identify and validate proteins and gene targets associated with colon cancer | The goal is to develop a program using activity-based proteomics on colon cancer specimens to identify new targets suited for diagnostic and therapeutic development |
| Genomics Collaborative Inc. | Exelixis Corp. (EXEL), Pharmacia Corp. and GlaxoSmithKline plc, along with two others | Agreements for GCI Access designed to provide researchers with access to a database of clinical data and DNA, tissue and sera samples | GCI Access enables researchers to accelerate the validation process |
| Geron Corp. (GERN) | Clone International Pty. Ltd. (Australia) and AgResearch Ltd. (New Zealand) | Agreement to exclusively license its nuclear transfer technology for use in Australia and New Zealand | The rights will allow Clone and AgResearch to use Geron's nuclear transfer technology to produce superior cattle and sheep for agricultural applications; Geron will receive a 25% equity interest in Clone and a share of Clone's future revenues |
| Graffinity Pharmaceutical Design GmbH (Germany) | Biosearch Italia SpA (Italy) | Alliance to discover and develop antibiotic products | Biosearch will use Graffinity's drug discovery technology to identify compounds against targets identified by Biosearch |
| Hyalose LLC (unit of Emergent Technologies Inc.) | Novozymes A/S (Denmark) | Multimillion-dollar joint development and option agreement to genetically produce hyaluronic acid and its variations based on Hyalose recombinant technology | Hyalose will receive from $8M to $10M if all options and milestones are met; it also will receive royalties from the product's commercialization |
| ICOS Corp. (ICOS) | Seattle Genetics Inc. (SGEN) | Agreement in which Seattle Genetics will perform process development scale-up and GMP manufacturing on SGN-15; also, an agreement to develop SGN-30 | Financial terms were not disclosed |
| ICOS Corp. (ICOS) | Array BioPharma Inc. (ARRY) | Agreement to discover and develop small-molecule drugs directed at disease targets containing the I-domain allosteric site structural motif | ICOS will provide research funding for two years; it also will be responsible for clinical development and commercialization; Array will receive milestones and royalties |
| Incyte Genomics Inc. (INCY) | Corvas International Inc. (CVAS) | Multiyear subscription agreement for Incyte's LifeSeq Gold database to advance Corvas' cancer research and development programs focused on proteases | Terms were not disclosed |
| Invitrogen Corp. (IVGN) | Cell Genesys Inc. (CEGE) | Licensing agreement for the lentiviral gene delivery technology for commercialization in the research market | Cell Genesys will receive royalties on sales and a share of any sublicense payments |
| LION bioscience AG (Germany; LEON) | Genomics Collaborative Inc. | Licensing agreement for LION's SRS platform | The platform will be used to access GCI's databases of patient clinical and sample information, as well as public biological data sources via one portal |
| MDS Inc. (Canada; TSE:MDS; NYSE:MDZ) | Signature BioScience Inc. | Agreement worth a minimum of $10M that calls for MDS to develop Signature's microwave spectroscopy instrumentation | Up-front fees to Signature will total $10M, and other milestone and royalty payments also are part of the package; MDS gains exclusive license rights to commercialize research instrumentation and peripherals based on microwave spectroscopy instrumentation |
| Medarex Inc. (MEDX) | Genesto A/S (Denmark) | Partnership to discover therapeutic antibodies | Medarex will use its UltiMab System to create antibody leads to target proteins supplied by Genesto |
| Neuralstem Inc. | MetriGenix Inc. | Agreement to jointly develop and market a series of neurochips as low-density, theme-based oligonucleotide microarrays based on MetriGenix's Flow-thru Chip technology | Neuralstem will contribute content from its discovery efforts using human central nervous system stem cells |
| Omnimmune Corp. | CytoGenix Inc. (OTC BB:CYGX) | Research agreement in which Omnimmune will use its antibodies to carry CytoGenix's DNA strands to treat cancer | Each company will be responsible financially for part of the research |
| Oxagen Ltd. (UK) | Cerylid Biosciences Ltd. (Australia) | Collaboration to investigate the genetics of endometriosis | The study will include more than 1,300 families in which at least two sisters are affected with endometriosis, together with their relatives |
| Physiome Sciences Inc. | 3rd Millennium Inc. | Licensing agreement for the PathwayPrism biological modeling technology to use in conjunction with data integration technology | It will allow 3rd Millennium and its academic collaborators to visualize and simulate pathways and associated networks related to Huntington's disease |
| QLT Inc. (QLTI) | Xenova Group plc (UK; XNVA) | Licensing agreement for XR9576 | QLT will use the product in its oncology programs; QLT is paying a $10M license fee up front and may pay as much as $50M in milestones; it also will fund up to $45M for Phase III trials in North America and Europe; Xenova will benefit from royalties between 15% and 22% |
| Rosetta Inpharmatics Inc. (RSTA) | Europroteome AG (Germany) | Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System | Financial terms were not disclosed |
| Sequitur Inc. | Rigel Pharmaceutical Inc. (RIGL) | Agreement to provide access to Sequitur's antisense functional genomics technology | The multiyear agreement stipulates a supply of Sequitur's antisense compounds, sequence selection and transfection methods will go to Rigel, which will pay research support, antisense material charges and licensing fees |
| Silicon Genetics Inc. | Exelixis Inc. (EXEL) | Licensing agreement for the GeNet database | The database will be used in Exelixis' integrated discovery platform |
| Solvay Pharmaceuticals BV (Belgium) | BioSante Pharmaceuticals Inc. (OTC BB:BTPH) | Sublicensed agreement for U.S. and Canadian rights to an estrogen/progestogen combination transdermal hormone replacement gel product | Solvay now holds worldwide rights to the product, excluding Japan and Korea; the agreement involves an initial payment of $2.5M, future milestone payments and sales-based royalties |
| The Genetic Company Inc. (Switzerland) | Discovery Technologies Ltd. (Switzerland) | Collaboration to identify precursors for drug leads to treat colon cancer | The companies will test thousands of chemical substances in a high-throughput screen for their ability to block the activity of cellular proteins that trigger cell division |
| Thermo Finnigan Inc. (division of Thermo Electron Corp.) | Proteome Systems Inc. (Australia) | Partnership to develop total solutions for proteomics research | Proteome Systems will augment its integrated proteomics technology system, ProteomIQ, by incorporating several Thermo Finnegan products; Thermo Finnigan will have access to Proteome Systems' sample preparation technology for the electrospray mass spectrometer |
| Tranzyme Inc. | NeoGenesis Drug Discovery Inc. | Collaboration combining Tranzyme's expertise in protein expression with NeoGenesis' chemical genomics | TExT will be used to bolster NeoGenesis' chemistry-based genomics program; NeoGenesis will supply Tranzyme with multiple sets of therapeutic, disease-associated gene sequences, which Tranzyme will test on different mammalian cells |
| Trimeris Inc. (TRMS) | Array BioPharma Inc. (ARRY) | Agreement to discover small-molecule fusion inhibitors of HIV and respiratory syncytial virus | Companies will collaborate to identify preclinical candidates and Trimeris will be responsible for further development; Array will be entitled to receive payments and royalties based on achievement of certain developmental milestones |
| Valentis Inc. (VLTS) | Lexicon Genetics Inc. (LEXG) | Nonexclusive licensing agreement for GeneSwitch gene regulation technology | The license is for research purposes only and involves an up-front payment and annual maintenance fees |
| Vitrolife AB (Sweden; SSE:VITR) | Millenium Biologix Inc. (Canada) | Agreement for the development and testing of Vitrolife's culture media for use in human tissue engineering, particularly cartilage and bone | The agreement will cover a period of comprehensive testing and evaluation of candidate media produced by Vitrolife, based on models established by Millenium |
| Xanthon Inc. | Chiron Corp. (CHIR) | Collaboration to explore the development of a system to detect the presence of infectious agents in clinical samples using Xanthon's technology and Chiron's nucleic acid sequences | Xanthon will conduct these studies using its electrochemical DNA detection system and Chiron's HCV insert |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Arakis Ltd. (UK) | SkyePharma plc (UK; SKYE; LSE:SKP) | Agreement to jointly develop a novel tissue-remodeling agent to treat chronic obstructive pulmonary disease | Arakis will contribute initial intellectual property for AD 313, and SkyePharma will contribute its inhalation formulation and device technology |
| Arena Pharmaceuticals Inc. (ARNA) | ICI group (UK) | Agreement to apply Arena's CART technology to olfactory and gustatory G protein-coupled receptors | The initial stage of research will last at least six months; Arena will use CART to develop olfactory and/or gustatory GPCR assays and then screen compounds |
| Arius Research Inc. (Canada; CDNX:YAR) | Goodwin Biotechnology Inc. | Contract to manufacture supplies of Arius' antibodies, AR460-23 and AR5LAC-20 | Goodwin will manufacture the antibodies for upcoming cancer studies in humans |
| Arius Research Inc. (Canada; CDNX:YAR) | QualTek Molecular Laboratories | Agreement to conduct target validation studies for Arius' cancer-killing antibodies, AR460-23 and AR5LAC-20 | Financial terms were not disclosed |
| Aurora Biosciences Corp. (ABSC) | Hyseq Inc. (HYSQ) | Two-year deal for screening Hyseq's orphan secreted protein collection | Aurora will get up-front payments, licensing fees and technology access fees, and could get performance and development milestones, as well as royalties |
| Biogen Inc. (BGEN) | ICOS Corp. (ICOS) | Collaboration to develop and commercialize oral therapeutics to treat inflammatory conditions | Companies will split profits equally, and they will co-promote any products, as well as share the costs of development; ICOS will receive an $8M up-front payment, as well as possible milestone payments |
| Biomax Informatics AG (Germany) | Millennium Pharmaceuticals Inc. (MLNM) | Licensing agreement for the BioRS Integration and Retrieval Plus system | Millennium will use the high-speed data retrieval system as a bioinformatics tool as part of its existing technology platform |
| Blue Heron Biotechnology Inc. | Amgen Inc. (AMGN) | Exclusive worldwide license agreement to a gene synthesis patent issued to Amgen | The patent describes procedures for the synthesis of linear double-stranded DNA; Blue Heron has the right to sublicense, but Amgen retains rights to practice under the patent |
| Charles River Laboratories International Inc. (NYSE:CRL) | Sangamo BioSciences Inc. (SGMO) | Technology partnership agreement to apply Sangamo's gene regulation technologies to the creation of transgenic rat research models | The collaboration initially will involve the creation of a novel rat model for use in developing new drugs and therapies for cancer |
| Chiron Corp. (CHIR) | Genetronics Biomedical Corp. (AMEX:GEB) | Collaborative agreement to explore using Genetronics' electroporation platform to deliver certain DNA vaccines into cells in vivo | Financial details were not disclosed |
| Commonwealth Biotechnologies Inc. (CBTE) | bayMountain Inc. | Agreement to develop and commercialize methods to help interpret and mine the data present in genome databases | The companies signed a letter of intent to develop and commercialize the methods |
| Consensus Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. (VRTX) | Collaborative agreement in which Consensus will provide substrates and chemical analysis of the catalytic site requirements for 10 targets in the protease gene family | Agreement also will entail the cloning, production and kinetic assessment of novel protease targets; Vertex has the right to develop and market products resulting; Consensus will receive certain research support and milestone payments |
| Curis Inc. (CRIS) | Micromet AG | Joint research, product development and technology exchange alliance combining the companies' expertise to find targets for antibody development | Curis will receive a $14M up-front payment, and also gain exclusive rights to Micromet's single-cell genomics technology for stem cell and genomics research |
| Cytochroma Inc. (Canada) | Allergan Inc. (NYSE:AGN) | Expanded research, development and license agreement to develop inhibitors of retinoic acid metabolism | The agreement extends the collaboration for up to three years and includes additional milestone payments and increased royalty streams on product sales |
| DeCode genetics Inc. (Iceland; DCGN) | Affymetrix Inc. (AFFX) | Collaboration aimed at developing DNA-based tests to predict the responsiveness of patients to treatments for common diseases, including high cholesterol, depression, asthma, hypertension, breast cancer, schizophrenia and migraines | The work will combine deCode's population-based approach to pharmacogenomics and Affymetrix's GeneChip technology; the value of the deal for deCode is in the sales of the product, rather than in up-front payments |
| DeCode genetics Inc. (Iceland; DCGN) | Applied Biosystems Group (NYSE:ABI) | Three-year alliance to combine deCode's bioinformatics tools for genotypic analysis and Applied Biosystems' bioanalytical instruments to build capabilities for DNA research | Companies intend to adapt deCode's genotyping software suite for integration with Applied's laboratory management software to provide customizable solutions for the generation, management and analysis of genotyping data |
| Discovery Partners International Inc. (DPII) | Maxia Pharmaceuticals Inc. | Agreement focusing on a new class of biological targets | Maxia has exclusive rights to develop and commercialize all of the compounds resulting from the deal |
| DNAPrint genomics Inc. (OTC BB:DNAP) | DNAPRO SDN BHD (Malaysia) | Joint venture agreement to expand DNAPrint's pharmacogenomics presence overseas | The joint venture is called DNAPrint genomics SDN BHD; it will develop genomics-based products geared for Malaysian, Indonesian and other Southeast Asian populations |
| Epigenomics AG (Germany) | Cancer Research Ventures Ltd. (UK) | Worldwide exclusive licensing agreement for a DNA methylation-based diagnostic test | Epigenomics will develop and commercialize the novel methylation detection assay as an alternative technology for the development of diagnostic tests |
| Exact Sciences Corp. (EXAS) | Laboratory Corp. of America Holdings (NYSE:LH) | Agreement for the licensing of Exact's genomics-based technologies | Under the agreement, for a specific length of time, LabCorp will be the only laboratory to offer testing services based on certain Exact Science technology for the detection of colorectal cancer; Exact will receive an up-front payment and licensing fees |
| Fludigm Corp. | Axon Instruments Inc. | Collaboration in which Fludigm researchers will combine their expertise in microfluidics with Axon's instrumentation knowledge | Companies will develop chips that capture and manipulate individual cells |
| Gene Logic Inc. (GLGC) | PsychoGenics Inc. | Subscription agreement to a CustomSuite of the GeneExpress Suite, as well as a collaboration | Collaboration is focused on central nervous system tissue samples |
| GeneMachines Inc. | Incyte Genomics Inc. (INCY) | Licensing agreement to U.S. patents and their foreign equivalents that cover fundamental methods for fabricating microarrays of biological samples on solid substrates | The agreement will enable GeneMachines to sell its OmniGrid and OmniGrid Accent microarrays with a label license for research use that allows end users to practice the methods for printing microarrays |
| Genencor International Inc. (GCOR) | Epimmune Inc. (EPMN) | Collaboration for the development of vaccines against hepatitis C, hepatitis B and human papillomavirus | Collaboration is for 30 months, but is extendable; it is potentially worth $60M |
| Genomic Solutions Inc. (GNSL) | NuTec Sciences Inc. | Collaborative agreement to expand and enhance the bioinformatics technology capabilities of Genomic Solution's GeneTAC Biochip system | NuTec will work with Genomic Solutions to design and develop the new software |
| Genomic Solutions Inc. (GNSL) | ProteoMetrics Inc. | Agreement to develop proteomics software | The companies will create a bioinformatic product integrating Genomic Solutions' Investigator Protein Warehouse data integration software with ProteoMetrics' Radars system for mass spectrometry data analysis; Genomic Solutions also will distribute ProteoMetrics' existing software products and has a first right of refusal to acquire ProteoMetrics |
| Genta Inc. (GNTA) | EpiGenesis Pharmaceuticals Inc. | Licensing agreement for several patents that involve methods, compositions and processes for in vitro and in vivo inhibition of protein synthesis by antisense oligonucleotides | The nonexclusive agreement includes an up-front cash payment to Genta, along with royalty payments on product sales |
| Genzyme Diagnostics (unit of Genzyme General; GENZ) | SYN-X Pharma Inc. (Canada; CDNX:SYY) | Agreement to develop, manufacture and commercialize a technology for diagnosing, distinguishing, managing and monitoring stroke | The agreement supercedes prior agreements between the businesses regarding this technology and resolves all disputes between them |
| HiberGen Ltd. (Ireland) | Sequenom Inc. (SQNM) | Exclusive license agreement to SNaPIT genotyping technology for use with mass spectrometry | Sequenom has the right to develop and commercialize reagent kits and software based on HiberGen's technology for use with its MassARRAY high-throughput screening technology |
| Hybrigenics SA (France) | Oxford GlycoSciences plc (UK) | Collaboration to improve the selection and prioritization of Oxford's candidate targets, with the potential to discover new targets | Hybrigenics will use its high-throughput functional proteomics technology to identify proteins that interact with a selection of Oxford targets; the data will be owned equally by both companies; Oxford will provide research funding and will have an option to obtain the exclusive rights to commercialize resulting data |
| Incyte Genomics Inc. (INCY) | Secant Technologies Inc. | Partnership to market and further develop Incyte's Genomics Knowledge Platform | Secant gains the exclusive license to assume further development and marketing of GKP; Incyte will make an equity investment in Secant |
| Inpharmatica Ltd. (UK) | Serono SA (Switzerland; NYSE:SRA) | Two-year collaborative agreement for the discovery of novel protein therapeutics | Serono will provide research funding and will have the right to select an unlimited number of proteins for clinical development and commercialization; Inpharmatica will receive a series of undisclosed payments and potential royalties, as well as milestone payments that could exceed $20M |
| Isis Pharmaceuticals Inc. (ISIP) | Celera Genomics Group (NYSE:CRA) | Agreement to identify the roles of more than 200 novel genes, evaluating their roles in cancer, angiogenesis, inflammation and metabolic diseases | Isis will maintain rights to develop antisense drugs from the genes and Celera will have the right to select up to 10% of the genes as exclusive targets in developing therapeutic agents |
| Lexicon Genetics Inc. (LEXG) | Immunex Corp. (IMNX) | Two-year drug target validation agreement in which Lexicon will use its technologies to develop knockout mammalian models for targets in Immunex's internal drug discovery programs | Lexicon will receive an up-front technology access fee and annual research funding, as well as milestones and royalty payments |
| LION bioscience AG (Germany; LEON) | MDL Information Systems Inc. | Software licensing and reselling agreement | LION will license a range of MDL's informatics applications and databases in order to develop and commercialize software applications to interface with MDL's products; MDL will be the exclusive reseller for LION's iDEA product line |
| Lynx Therapeutics Inc. (LYNX) | BASF-LYNX Bioscience AG (joint venture by Lynx and BASF AG; Germany) | Extended technology licensing agreement until Dec. 31, 2007 | BASF-LYNX's right is extended to use Lynx's Massively Parallel Signature Sequencing and Megasort technologies; BASF-LYNX will pay Lynx a multimillion-dollar technology license fee |
| Medarex Inc. (MEDX) | Human Genome Sciences Inc. (HGSI) | Agreement to use the UltiMAb System to create antibody leads | Medarex will get license fees, milestone payments, and is entitled to royalties |
| Millennium Pharmaceuticals Inc. (MLNM) | Pharsight Corp. (PHST) | Agreement to evaluate and apply Pharsight's computer-assisted trial design and methodologies to Millennium's drug development programs | Agreement will focus initially on testing and validating the utility of Pharsight's modeling and simulation software in LDP-341, a cancer treatment in Phase II trials |
| NeoGenesis Inc. | Biogen Inc. (BGEN) | Expanded agreement from target identification to the screening of drug leads from Biogen's proteins | NeoGenesis will receive up-front payments and research and development funding, as well as milestone payments and royalties |
| NeoGenesis Inc. | Celltech Group plc (UK; NYSE:CLL) | Research collaboration in which Celltech will provide the disease targets and NeoGenesis will use its chemical genomics technology to screen for drug leads | NeoGenesis gets a $10M equity investment from Celltech, several years of research funding, and potential milestone payments |
| Oxxon Pharmaceuticals Inc. | Isis Innovation (technology transfer company at the University of Oxford) | Licensing agreement for intellectual property on adenovirus vaccine technology | The license covers the worldwide exclusive use of adenovirus vaccine to boost an immune response to an antigen for therapeutic and prophylactic applications in the fields of infectious disease and cancer |
| Peregrine Pharmaceuticals Inc. (PPHM) | Oakwood Laboratories LLC | Joint development agreement to evaluate therapeutic agents that combine Peregrine's tumor necrosis therapy tumor-targeting technology with Oakwood's anticancer liposome technology | Financial terms were not disclosed |
| Synt:em (France) | SangStat Inc. (SANG) | Three-year research collaboration for the discovery of next-generation RDP58 molecules | The focus of the collaboration will be to develop novel RDP58-like compounds for the inhibition of inflammation in new in vivo applications |
| Third Wave Agbio Inc. | ValiGen | Agreement in which Third Wave Agbio will develop and supply custom-designed Invader assays to ValiGen | ValiGen will use the platform to analyze genetic variations in several plant species |
| VaxGen Inc. (VXGN) | BBI Biotech (subsidiary of Boston Biomedica Inc.; BBII) | Agreement to collect, process and store white blood cells and seminal plasma in VaxGen's Phase III trial of its AIDS vaccine in North America and Europe | VaxGen will receive $488,750 over the life of the program under a subcontract with BBI, which is funding the work under a National Institute of Allergy and Infectious Diseases contract |
| Vical Inc. (VICL) | Merial (joint venture between Merck and Co. Inc. and Aventis SA, of Germany) | Agreement to extend options under a 1995 deal for developing and commercializing vaccines for animal health applications using Vical's naked DNA technology | Vical will receive $1M and Merial will receive a renewable one-year extension of its options against additional infectious disease targets in domesticated animals; Vical also will receive royalties for any vaccines sold |
| Xanthon Inc. | Xenometrix Inc. (subsidiary of Discovery Partners International Inc.; DPII) | Worldwide license agreement for access to gene expression profiling claims in U.S. and European patents | The nonexclusive license covers the collection of gene expression profiles using all platforms, including biochips, high-density microarrays and other high-throughput methods |
| Zyomyx Inc. | BD Biosciences (division of Becton, Dickinson and Co.; NYSE:BDX) | Supply and collaboration agreement for the development of Zyomyx's high-density protein biochips | BD Biosciences will develop, manufacture and supply antibodies for Zyomyx's research platform |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Aastrom Biosciences Inc. (ASTM) | Neoprobe Corp. (OTC BB:NEOP) | Development collaboration for a new immune system cell therapy product for cancer treatment | Collaboration will integrate Neoprobe's lymph node lymphocyte cell technology with Aastrom's AastromReplicell system and lymphocyte production technologies |
| Abgenix Inc. (ABGX) | Biogen Inc. (BGEN) | Agreement to generate fully human monoclonal antibodies for up to 15 Biogen-supplied antigen targets using XenoMouse technology | Abgenix will receive up-front research payments and possible license and milestone payments, as well as royalties on sales; Biogen is responsible for product development, manufacturing and commercialization of any products |
| Abgenix Inc. (ABGX) | Centocor Inc. | Expanded research agreement from December 1998 using Abgenix's XenoMouse technology | Collaboration will use the technology to generate fully human monoclonal antibody therapies against multiple antigen targets in a variety of indications |
| AlphaGene Inc. | Questar | Bioinformatics outsourcing and small-molecule research collaboration | AlphaGene will offer putative proteins, while Questar will provide bioinformatics support for structure determination, pathway identification, small-molecule ligand library creation and in silico screening of small molecules; Questar also will make an equity investments in AlphaGene |
| AltaRex Corp. (Canada; OTC BB:ALXFF; TSE:AXO) | Epigen Inc. | Joint collaboration to develop antibody-based treatments for up to 12 cancers associated with the human carcinoma antigen | Companies will actively and equally participate in the research; terms still to be negotiated; no money will be exchanged; any resulting technology developed would be shared by both, as would any revenue; any intellectual property created will be retained by the developing company |
| Aphios Corp. | ITC/Immune Technology | Exclusive worldwide development, manufacturing and commercialization collaboration centered on a natural therapeutic for hepatitis C | The companies will share costs and revenues associated with research, development and marketing |
| Avecia Biotechnology (UK) | XOMA Ltd. (XOMA) | License agreement for patented bacterial cell expression system technology | Technology includes the araB promoter system, pelB secretion system and a genetically engineered E. coli host-cell line; financial terms were undisclosed |
| BD Biosciences (a division of Becton, Dickinson and Co.; NYSE:BDX) | Dyax Corp. (DYAX) | Agreement to discover antibodies using Dyax's phage display technology | BDB has obtained rights to antibodies identified using Dyax's human antibody library and screening technology; it will have the exclusive right to market the antibodies as research products to the life science market, but Dyax retains all rights to the antibodies in the therapeutic field |
| Bionomics Ltd. (Australia) | Ozgene Pty. Ltd. (Australia) | Strategic alliance to develop treatments involving three genes believed to be involved in breast cancer | Bionomics owns the rights to the genes; Ozgene will help in development work, in return for a share of the royalties on any products that result |
| Boston Probes | Human Genetic Signatures Pty Ltd. (Australia) | Development and license option agreement focusing on epigenetics and personalized medicines | Boston Probes will grant Human Genetic Signatures a license to use and sell products based on peptide nucleic acid technology in return for an equity stake, milestone fees and royalties |
| Cambridge Antibody Technology Group plc (UK; LSE:CAT) | Xerion Pharmaceuticals GmbH (Germany) | License agreement for CAT's human phage antibody libraries and underlying intellectual property | Use of licensed technology for target discovery and validation and for functional proteomics work; CAT receives an undisclosed license fee for the technology; further financial details were not disclosed |
| Celera Genomics Inc. (NYSE:CRA) | DNA Sciences Inc. | Multiyear subscription agreement | DNA Sciences will access the Celera Discovery System to use Celera's database products, bioinformatics systems and other discovery tools in its research |
| Crucell NV (the Netherlands; CRXL) | Selective Genetics Inc. | Nonexclusive license to Crucell's PER.C6 cell line | Crucell will manufacture clinical-grade batches of the PER.C6-derived gene therapy product and will receive up-front and annual payments, as well as additional fees and potential royalties |
| Crucell NV (the Netherlands; CRXL) | Vaxin Inc. | Development agreement for two new types of vaccines suitable for injection-free administration | Companies will combine Crucell's PER.C6 cell line and related vaccination technology with Vaxin's skin delivery system for vaccines, EasyVax; companies will share profits and costs |
| Dragon Pharmaceuticals Inc. (OTC BB:DRUG) | Alphatech Bioengineering Ltd. (Hong Kong) | Rights agreement to technology related to the production of a hepatitis B vaccine | The purchase price was $4M |
| Epimmune Inc. (EPMN) | Pharmexa A/S (Denmark; CSE:PHARMX) | Non-exclusive license agreement to PADRE technology | The license covers Pharmexa's use of PADRE toward five target antigens; financial terms include up-front fees, product sales royalties and milestone payments |
| Evotec OAI (Germany; unit of Evotec Biosystems AG; Neuer Markt:EVT) | MelTec GmbH (Germany) | Joint venture that will specialize in the discovery and development of treatments for autoimmune diseases and cancer | The venture will combine Evotec's discovery platform and MelTec's Whole-Cell Protein Fingerprinting proteomics technology; ownership of the new company will be split evenly |
| Genmab A/S (Denmark; CSE:GEN) | deCODE genetics Inc. (DCGN) | Collaboration in which deCODE contributes novel targets for studies covering cardiovascular and inflammatory diseases, as well as cancer; a second agreement is for the development of a DNA-based test to predict individual clinical response to Genmab's HuMax-CD4 | Companies will share development costs and profits in the first agreement; Genmab will provide committed research funding and potential milestone payments in the second agreement |
| Genomics One Corp. (Canada; MSE:GNX) | WITA Proteomics AG (Germany) | Strategic marketing agreement for WITA's high-resolution proteomics platform | Genomics One will market the platform in North America |
| Genzyme Molecular Oncology (GZMO) | BruCells SA/NV (Belgium) | Exclusive license agreement to patent rights covering fusion of dendritic cells and tumor cells | Genzyme will sponsor a two-year research program at BruCells related to the technology |
| Geron Corp. (GERN) | Viragen Inc. (AMEX:VRA) | Option agreement to license nuclear transfer technology | Viragen can license the technology on a nonexclusive worldwide basis; Geron will receive cash and Viragen stock |
| Incyte Genomics Inc. (INCY) | Lexicon Genetics Inc. (LEXG) | Collaboration aimed at developing therapeutic protein drug products | Each company will select 250 secreted proteins for functional characterization, and Lexicon will apply its in vivo mammalian validation technologies to determine therapeutic utility; companies will share discoveries and rights; agreement includes milestone and royalty payments for each |
| Innapharma Inc. | Quintiles Transnational Corp. (QTRN) | Nonexclusive preferred provider agreement for planning and implementing a clinical program for Innapharma's lead candidate, INN 00835, in clinical depression | Quintiles will become Innapharma's clinical research provider of choice, and will make an undisclosed equity investment in Innapharma |
| Inspire Pharmaceuticals Inc. (ISPH) | Allergan Inc. (NYSE:AGN) | Licensing, development and marketing deal for dry-eye products | The agreement covers Inspire's INS365 Ophthalmic and Allergan's Restasis; Inspire could receive up to $39M in up-front and milestone payments |
| Inspire Pharmaceuticals Inc. (ISPH) | Genentech Inc. (NYSE:DNA) | Agreement returning rights to P2Y2 agonists for treatment of respiratory disorders back to Inspire | The reacquisition of rights will be at no cost to Inspire, which has received $16M from the deal started in December 1999 |
| InterMune Inc. (ITMN) | Amgen Inc. (AMGN) | Licensing agreement for Infergen | InterMune is licensing Infergen from Amgen for $21M in up-front payments, $8M in near-term milestones and royalties on sales |
| KS Biomedix Holdings plc (UK) | Babraham Bioscience Technologies Ltd. (UK) | Agreement to form a company called Discerna Ltd. to be located in Cambridge, UK | Company will be an equal joint venture bringing together Babraham's ribosome display technology and KSB's therapeutic targets |
| Large Scale Biology Corp. (LSBC) | Plant Bioscience Ltd. (UK) | Agreement to combine Large Scale's high-throughput gene discovery capabilities with Plant Bioscience's portfolio of technologies | Large Scale gains an exclusive license to certain viral-delivered gene silencing and over-expression technologies and certain other viral-derived technologies |
| Luminex Corp. (LMNX) | Research and Diagnostic Systems Inc. (subsidiary of Techne Corp.) | Multiyear partnership to develop and market reagents based on Luminex's LabMAP technology | R&D Systems receives worldwide nonexclusive license to develop and distribute reagents in return for an up-front payment and royalties |
| MDS Proteomics Inc. (NYSE:MDZ) | Abgenix Inc. (ABGX) | Collaboration to develop and commercialize antibodies for a broad range of disease areas | Companies will receive reciprocal milestone and royalty payments related to commercialized products; Abgenix will purchase $15M in MDS stock |
| Medarex Inc. (MEDX) | Epicyte Pharmaceutical Inc. | Collaboration for the discovery, development and commercialization of antibody-based products | Medarex will use its UltiMAb Human Antibody Development System to generate antibodies to antigen targets; companies will share the costs and commercialization rights |
| Medarex Inc. (MEDX) | Genmab A/S (Denmark) | Expanded relationship in which Medarex will develop a fully human therapeutic antibody against inflammation with Genmab | The companies will share equally in costs of development and profits; Medarex will retain all rights and cost responsibilities for product development and commercialization in Asia |
| Medarex Inc. (MEDX) | Sangamo Biosciences Inc. (SGMO) | Agreement to develop and commercialize fully human antibodies using cell lines that overexpress selected G protein-coupled receptors | The pair will share costs and profits from the joint effort |
| MediChem Life Sciences (MCLS) | Elitra Pharmaceuticals Inc. | Three-year joint research program to discover and develop drug candidates against microbial infections | Companies will commit resources and share rights to the program; Elitra will reimburse MediChem for research conducted and may buy rights to drug candidates in exchange for milestone payments and royalties |
| MediChem Life Sciences (MCLS) | Neurocrine Biosciences Inc. (NBIX) | Two-year collaborative agreement in proteomics for new drug development | MediChem will crystallize and determine high-resolution 3-dimesional structures of specific G protein-coupled receptors; Neurocrine will provide access and milestone fees, as well as research funding |
| Microcide Pharmaceuticals Inc. (MCDE) | Cetek Corp. | Collaborative research and development agreement to discover and develop new classes of anti-infective agents | Microcide will pay Cetek milestones and will have worldwide development and commercialization rights on products that result |
| MorphoSys AG (Germany; Neuer Markt:MOR) | ImmunoGen Inc. (IMGN) | Collaboration that grants ImmunoGen a license to MorphoSys' HuCAL technology to generate research antibodies | Agreement is an extension of an October 2000 deal; the new agreement calls for ImmunoGen to pay MorphoSys technology access and annual subscription fees over four years |
| Myriad Genetics Inc. (MYGN) | Bioscientia Ltd. (Germany) | Exclusive collaboration to provide Myriad's family of BRAC-Analysis predictive medicine tests in Austria, Germany and Switzerland | Myriad will transfer technical know-how for site-specific mutation detection to Bioscientia |
| NicOx SA (France; Nouveau Marche:NICOX) | Biolipox (Sweden) | Research and co-development agreement on a class of nitric oxide-releasing respiratory therapeutics | NicOx will synthesize a series of new compounds |
| Orion Genomics LLC | ViaLactia Biosciences Ltd. (New Zealand) | Multistage genomics alliance to develop improved varieties of forage plant species for pastoral agricultural industries, and to develop hardier and higher-yielding crops | Orion's GeneThresher technology will be used to sequence and identify the complete gene set of a key forage grass species; companies will develop specialized genome research tools; financial details were not disclosed |
| Oxford GlycoSciences plc (UK; OGSI; LSE:OGS) | Marconi plc (UK; MONI; LSE:MONI) | Joint venture to specialize in the supply, hosting and management of proteomics databases | The company, Confirmant Ltd., will have initial funding of US$42M, which the founders will contribute equally in cash; Confirmant will pay Oxford for exclusive rights to proteome databases and a license to data analysis software |
| Oxford GlycoSciences plc (UK; OGSI; LSE:OGS) | NeoGenesis Inc. | Alliance to accelerate OGS's small-molecule discovery and development against protein targets derived from its high-throughput proteomics platform | OGS will provide potential protein targets and will provide research funding, milestone payments and royalties; it also will fund commercialization and make an equity investments in NeoGenesis |
| ProLinia Inc. | Geron Corp. (GERN) | Nonexclusive license for nuclear transfer technology for agricultural applications | ProLinia gains access to Geron's current and future issued patents and patent applications covering the technology for use in swine worldwide and bovine everywhere except Australia and New Zealand |
| ProSanos Corp. | Management Science Associates Inc. | Strategic alliance to pursue biomedical informatics projects | Part of the alliance creates an advanced biomedical data center |
| QLT Inc. (Canada; QLTI) | Kinetek Pharmaceuticals Inc. (Canada) | Research, development and license agreement for signal transduction inhibitors to treat eye, immune system and kidney diseases | QLT will make an initial C$11M equity investment in Kinetek; the deal is worth C$120M (US$80M) |
| Quark Biotech Inc. | ES Cell International Pte Ltd. (Singapore) | Joint human embryonic stem cell research program to discover the cause of human embryonic stem cell differentiation and self-renewal | The companies will use Quark Biotech's technology platform to discover new genes such as growth factors derived from hES cells |
| Sangamo BioSciences Inc. (SGMO) | Zycos Inc. | Collaboration to assess the utility of Zycos' gene transfer technology for the delivery of Sangamo's zinc finger DNA-binding protein transcription factor genes in vivo | Sangamo will evaluate the effectiveness of Zycos' gene expression system and biopolymer delivery system technologies |
| Seattle Genetics Inc. (SGEN) | Eos Biotechnology Inc. | Renewable multiyear collaboration using Eos' monoclonal antibodies with Seattle Genetics' toxic payload technology to specifically target and kill tumor cells | Eos will pay an up-front access fee, milestone payments and royalties on sales of resulting products; further financial details were not disclosed, but the milestones and up-front fee made it a multimillion-dollar deal per product, with single-digit royalties |
| Sequenom Inc. (SQNM) | Morphochem AG (Germany) | Agreement for two to three years that will focus on discovery and development of next-generation therapeutics to treat Type II diabetes mellitus and cancer | Each company will cover its own research costs and the two will equally share any results of the collaboration |
| Specialty Laboratories Inc. (NYSE:SP) | Axis-Shield plc (Scotland) | Agreement for exclusive U.S. rights to a new gene-based test for predisposition to osteoporosis | The test uses a UK-based Gemini Genomics plc (GMNI) patent on the Type 1 collagen gene |
| Syrrx Inc. | Cubist Pharmaceuticals Inc. (CBST) | Anti-infective drug discovery collaboration | The work will focus on bacteria and fungi |
| Vernalis Group plc (UK; LSE:VER) | Alcon Laboratories Inc. | Agreement to explore approaches to the treatment of glaucoma | Companies will assess molecules from the Vernalis research portfolio |
| Viron Therapeutics Inc. (Canada) | Xenova Group plc (UK; XNVA; LSE:XEN) | Licensing agreement for an undisclosed anti-inflammatory protein | Terms were confidential; Xenova will move forward with research of the protein |
| Xenerex Biosciences (unit of Avanir Pharmaceuticals Inc.; AMEX:AVN) | Peregrine Pharmaceuticals Inc. (PPHM) | Agreement in which Xenerex will take three Peregrine antigen targets for generation of fully human monoclonal antibodies | Peregrine will be responsible for product development, manufacturing and commercialization; Xenerex will receive up-front research fees and could earn milestones and royalties on future sales |
| Zonagen Inc. (ZONA) | Bridge Organics | Agreement to develop a commercially viable process for a new class of compounds to treat endometriosis | BDB has obtained rights to antibodies identified using Dyax's human antibody library and screening technology; it will have the exclusive right to market the antibodies as research products to the life science market, but Dyax retains all rights to the antibodies in the therapeutic field |
| Zygogen LLC | NuTec Sciences Inc. | Strategic partnership involving zebrafish | The alliance aims to accelerate Zygogen's ability to convert zebrafish into a target validation and screening model |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Affibody AB (Sweden) | Gyros AB (Sweden) | Strategic alliance to develop and commercialize an integrated and automated microfluidics-based protein microarray platform | Platform will combine Gyros' CD-based microlaboratories with Affibody's high-throughput, high-sensitivity protein microarrays |
| Agilent Technologies Inc. (NYSE:A) | MDS Proteomics Inc. (Canada; unit of MDS Inc.; NYSE:MDZ; TSE:MDS) | Agreement to develop new protein analysis technologies and products to speed the development of new medicines | The focus will be to develop specialized products that speed the process of identifying and analyzing proteins |
| Austrian Nordic Biotherapeutics AG (Austria) | EuroFerm GmbH (Germany) | Letters of intent to collaborate on the in vivo production of viral vectors, initially to treat cancer | No further details were disclosed |
| AVI BioPharma Inc. (AVII) | Medtronic Inc. (NYSE:MDT) | Licensing deal for antisense compound rights for vascular disease | Deal is potentially worth $100M; Medtronic gains a worldwide license to a family of antisense compounds that includes AVI's Resten-NG |
| Bio-Rad Laboratories Inc. (AMEX:BIO) | American Medical Laboratories Inc. | Agreement to provide testing for hereditary hemochromatosis | AML will provide testing services using Bio-Rad's DNA-based product line |
| Biosyn Inc. | Crompton Corp. (NYSE:CK) | Worldwide exclusive licensing agreement to develop Crompton's compound UC781 as a topical microbicide targeted against the AIDS virus | Biosyn will fund all development costs and give Crompton milestone and royalty payments; Crompton retains technology rights to all other indications |
| Chiron Corp. (CHIR) | Rhein Biotech NV (Germany) | Collaboration to develop, manufacture and market combination pediatric vaccines for sale through international organizations and in developing countries | Chiron will provide antigens for diphtheria, tetanus, pertussis and haemophilus influenza type B; Rhine will supply hepatitis B virus vaccine and manufacture the combination vaccines |
| Connetics Corp. (CNCT) | Prometheus Laboratories Inc. | Agreement selling the rights to Ridaura to Prometheus | Prometheus will pay $9M in cash plus a royalty on annual sales in excess of $4M for the next five years |
| Corixa Corp. (CRXA) | Biovation Ltd. (UK; unit of Merck Group) | Research collaboration to design antibodies | Biovation will use its DeImmunization technology to come up with antibodies in undisclosed areas; Biovation gets up-front research money, as well as license fees, potential milestones and royalties |
| Cytochroma Inc. (Canada) | Molecular Mining Corp. (Canada) | Collaboration to search for genes | The genes will enhance Cytochroma's library of validated molecular targets for drug discovery |
| Deltagen Inc. (DGEN) | Vertex Pharmaceuticals Inc. (VRTX) | Three-year collaboration to provide Vertex with access to Deltagen's DeltaBase product | Vertex will have nonexclusive access to a subset of DeltaBase that contains in vivo mammalian gene function information; Deltagen will receive certain milestone and royalty payments |
| Genencor International Inc. (GCOR) | Gyros AB (Sweden) | One-year collaboration to apply Gyros' microfluidic technology to Genencor's screening capabilities | Gyros will design applications and compact discs for Genencor's screening assays; Genencor will serve as a technical evaluation site |
| Genzyme Corp. (unit of Genzyme General; GENZ) | Zentaris AG (Germany) | Strategic collaboration for Genzyme to acquire a 5% stake, worth up to $14.2M, when Zentaris goes public in Germany | Genzyme will receive 900,000 shares of Zentaris stock for up to $14.2M; Genzyme gets limited rights of first refusal to future sales of shares following the initial public offering |
| Harvard Bioscience Inc. (HBIO) | NexGen Sciences Ltd. (UK) | Collaborative research and development agreement to develop tools to alleviate bottlenecks in the drug discovery process | Collaboration will focus on tools for protein isolation and ADMET screening |
| Hybridon Inc. (OTC BB:HYBN) | Isis Pharmaceuticals Inc. (ISIP) | Agreement for each other's intellectual property | Isis will pay a total of $34.5M for an exclusive license to all of Hybridon's antisense chemistry and delivery patents and technology; Hybridon gains access to Isis' RNase H suite of patents and will pay Isis $6M in stock over three years |
| Iconix Pharmaceuticals Inc. | Incyte Genomics Inc. (INCY) | Collaboration to develop and commercialize a next-generation chemogenomic information product | Incyte will market Iconix's ChemExpress and Iconix will integrate Incyte's LifeExpress Lead database into ChemExpress under a license; Incyte will make an equity investment in Iconix; financial terms were not disclosed |
| Immunex Corp. (IMNX) | Cambridge Antibody Technology Group plc (UK; LSE:CAT) | Collaboration to develop and commercialize human antibody-based therapeutics for autoimmune and inflammatory disorders | Collaboration calls for an equal split in research costs and profits |
| Incyte Genomics Inc. (INCY) | Genomic Health Inc. | Collaboration to use Incyte's genomic and proteomic databases, functional genomics technologies and intellectual property | Genomic Health will gain access to Incyte's LifeSeq Gold and BioKnowledge databases |
| Incyte Genomics Inc. (INCY) | Odyssey Pharmaceuticals Inc. | Collaboration on the functional characterization of proteins encoded by Incyte gene transcripts | Financial details were not disclosed |
| Infigen Inc. | Immerge BioTherapeutics Inc. (joint venture of Novartis Pharma AG and BioTransplant Inc.; BTRN) | Partnership to use nuclear transfer technology to develop swine with more human organs | Infigen will provide Immerge with exclusive access to its porcine NT technology; Immerge will provide the vectors for specific genes and cells from miniature swine |
| InforMax Inc. (INMX) | Abgenix Inc. (ABGX) | License agreement for GenoMax enterprise software | Abgenix gains access to GenoMax, which is designed to work with sequence information, gene expression data, protein structure and protein-protein interactions |
| InterMune Pharmaceuticals Inc. (ITMN) | MoliChem Medicines Inc. (OTC BB:MLCM) | Agreement to jointly develop and commercialize MoliChem's Moli1901 to treat pulmonary indications | InterMune will make a $1.5M up-front payment and milestone payments for each indication of use; companies will develop and commercialize the product worldwide and share equally in expenses and profits |
| Lexicon Genetics Inc. (LEXG) | Taconic Farms Inc. | Technology sublicensing program permitting academic research use of positive-negative selection and isogenic DNA technologies | The agreement is for the generation and use of transgenic and knockout mammalian models of human gene function |
| LION bioscience AG (Germany; LEON) | Affymetrix Inc. (AFFX) | Licensing agreement for LION's SRS data integration system | Affymetrix will use the system to build a web portal for its customers and for internal use; the portal will detail information on Affymetrix's GeneChip probe arrays |
| Lynx Therapeutics Inc. (LYNX) | AniGenics Inc. | Agreement to use Lynx's Megasort and Megatype technologies to identify genes associated with commercially valuable traits in certain food animal species | Lynx will receive payments and royalties on sales of products and services from AniGenics; it also retains rights to human health care applications of any discoveries |
| MDS Proteomics Inc. (Canada; unit of MDS Inc.; NYSE:MDZ; TSE:MDS) | IBM Life Sciences (unit of IBM) | Formation of non-profit organization named Blueprint to create the Biomolecular Interaction Network Database (BIND) | BIND will serve as a comprehensive source of protein interactions and will be accessible on the internet |
| Medarex Inc. (MEDX) | NovImmune SA (Switzerland) | Collaboration to develop fully human therapeutic antibodies | Medarex will use its UltiMAb Human Antibody Development System to generate antibodies to disease targets discovered by Novimmune, which will develop and commercialize the products; Medarex will receive license fees and milestone payments, as well as royalties on sales |
| Microcide Pharmaceuticals Inc. (MCDE) | Discovery Partners International Inc. (DPII) | Research collaboration to optimize the drug-like qualities of Microcide's antifungal compound series | Microcide used its microbial genomics VALID system to discover the compounds |
| Millennium Pharmaceuticals Inc. (MLNM) | Cambridge Drug Discovery Ltd. (UK) | Two-year collaboration to accelerate Millennium's preclinical research | Millennium gets access to Cambridge Drug Discovery's molecular pharmacology expertise, assay development technologies and fully automated high-throughput screening capabilities |
| NeoGenesis Inc. | Microcide Pharmaceuticals Inc. (MCDE) | Collaborative research and development agreement to discover and develop new classes of antibiotics | Microcide will have worldwide product development and commercialization rights on products that result from the collaboration |
| Partek Inc. | Large Scale Proteomics Corp. | Licensing agreement for Partek's Pro 2000 Statistical and Visual Data Analysis system for proteomics research | Financial details were not disclosed |
| Phytera Inc. | Gemin X Biotechnologies Inc. | Research collaboration to find novel treatments for cancer and other diseases | Phytera will receive an up-front technology access fee and research funding, as well as potential milestone payments and royalties from commercialized products |
| Protein Design Labs Inc. (PDLI) | Exelixis Inc. (EXEL) | Collaboration to discover and develop antibodies for use in cancer diagnosis, prevention and treatment | PDL will make a $30M investment in Exelixis through the purchase of a note convertible within a year into Exelixis stock; PDL also will provide $4M in annual research funding for two or more years |
| ProdiGene Inc. | Avant Immunotherapeutics Inc. (AVAN) | Collaboration to produce recombinant immunotherapeutic proteins in plants | Collaboration initially will focus on using ProdiGene's plant transgenic production system for the manufacture of an Avant lead compound |
| Ribozyme Pharmaceuticals Inc. (RZYM) | Archemix Corp. | Alliance to share intellectual property in proteomics and molecular diagnostics | Archemix gets a license and sublicense to RPI's intellectual property covering allosteric ribozyme technology in exchange for equity and a seat on the Archemix board; RPI also will receive a license to Archemix intellectual property |
| Rigel Pharmaceuticals Inc. (RIGL) | Albany Molecular Research Inc. (AMRI) | Agreement for medicinal chemistry services to support and accelerate Rigel's product development | Albany will provide expertise to accelerate optimization of compounds in Rigel's mast cell program; financial details were not disclosed |
| Scios Inc. (SCIO) | Medtronic Inc. (NYSE:MDT) | Research collaboration to study the effects of Scios' Natrecor in combination with Medtronic's heart failure devices and implantable fusion systems | The first study will begin this quarter in Sweden |
| Symyx Technologies Inc. (SMMX) | Rhodia (France; CAC:RHA) | Research and development agreement to discover materials relevant to Rhodia's specialty chemical business | Rhodia will fund Symyx's discovery efforts and will get exclusive rights to commercialize resultant materials; Rhodia will make payments to Symyx |
| Targeted Growth Inc. | CropDesign NV (Belgium) | Research collaboration and technology cross-licensing agreement to develop cereal crops | TGI will supply its yield-enhancing genes for use in CropDesign's high-throughput TraitMill system and for use in commercial development in cereal crops |
| ValiGen NV | Agricore (farmer-owned cooperative) | Agreement to develop and market specialty canola products | ValiGen and Agricore will develop products using ValiGen's Genoplasty system to change specific DNA sequences |
| Xenerex Biosciences (subsidiary of Avanir Pharmaceuticals Inc.; AMEX:AVN) | Eos Biotechnology Inc. | Antibody agreement for Xenerex to generate fully human monoclonal antibodies to three cancer-target antigens provided by Eos | Xenerex will receive research fees and could receive license fees and milestones, plus royalty payments on sales; Eos will be responsible for manufacturing, product development and marketing of any products |
| Zygogen LLC | Ariad Pharmaceuticals Inc. (ARIA) | Collaboration to develop a joint technology platform based on Ariad's gene regulation technology and Zygogen's transgenic zebrafish models | Collaboration will combine Ariad's Argents system with Zygogen's Z-tag fluorescent-tagging technology |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Affymetrix Inc. (AFFX) | GeneData AG (Switzerland) | Nonexclusive co-marketing agreement for the GeneData Expressionist software | Affymetrix will promote and recommend Expressionist software for use with its products and software solutions |
| Arena Pharmaceuticals Inc. (ARNA) | Axiom Biotechnologies Inc. | Collaborative research program to develop and share information related to the localization of known G protein-coupled receptors within Axiom's human cell lines | Arena will have exclusive ownership of the information and Axiom's small-molecule data; Arena will purchase a $2M equity stake in Axiom |
| Atrix Laboratories Inc. (ATRX) | MediGene AG (Germany) | European marketing agreement for Atrix's Leuprogel products | Agreement is worth $20M for Atrix, $2M up front, $4M in stock and $14M in milestone payments |
| Aurora Biosciences Corp. (ABSC) | Integrative Proteomics Inc. | Collaboration and license agreement to generate a set of about 3.5M "data points" at Aurora's discovery facility using Integrative's targets | Integrative will license Aurora's high-throughput Big Biology and chemistry platforms and will gain access to a collection of more than 500,000 compounds; Integrative will pay an up-front technology access fee, license fees and support research; Aurora will receive revenues on certain products and will make an equity investment in Integrative |
| Avalon Pharmaceuticals Inc. | Compugen Ltd. (CGEN) | Collaboration to identify and develop drug targets and diagnostic markers through the license of Compugen's Gencarta annotated genome, transcriptome and proteome database and query tools | Compugen will receive cash payments and an equity stake in Avalon; Avalon gets complete rights to develop resulting therapeutic and diagnostic products |
| AVI BioPharma Inc. (AVII) | Exelixis Inc. (EXEL) | Five-year collaboration for antisense drug discovery research and development | AVI will provide its Neugene morpholino antisense agents to Exelixis, and will perform preclinical and clinical studies on antisense drug candidates; candidates will be jointly owned and Exelixis has a codevelopment option |
| Biogen Inc. (BGEN) | Rosetta Inpharmatics Inc. (RSTA) | Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System | Biogen will use the system in its drug discovery processes |
| Biomax Informatics AG (Germany) | Softberry Inc. | Strategic agreement granting Biomax an exclusive worldwide license to Softberry's complete human genome database | Biomax will develop and annotate the database to create the Pedant Human Genome Database |
| Celltech Group plc (UK; NYSE:CLL) | Evotec OAI (Germany; unit of Evotec BioSystems AG; Neuer Markt:EVT) | Agreement in which Evotec will apply its virus-like particle (VliP) technology to two of Celltech's G protein-coupled receptor targets | Celltech will have the option to obtain a nonexclusive license to use the VliP technology; agreement includes an up-front payment, annual fees and milestone payments |
| Cell Therapeutics Inc. (CTIC) | US Oncology Inc. (USON) | Research services agreement for the execution of up to five clinical studies in colorectal and lung cancers with PG-TXL | Financial details were not disclosed |
| Dendreon Corp. (DNDN) | Covance Biotechnology Services Inc. (subsidiary of Covance Inc.) | Contract agreement to produce antigen used to prepare Provenge for commercial launch | Provenge is Dendreon's prostate cancer vaccine in Phase III trials |
| Diversys Ltd. (UK) | Peptech Ltd. (Australia; ASX:PTD) | Research collaboration agreement to develop single-domain antibody drug candidates against four Peptech targets | Collaboration will generate $10M for Diversys, plus royalties |
| DNAPrint Genomics Inc. (OTC BB:DNAP) | Acculab of South Florida | Agreement to collect and phenotype volunteer blood samples | Relationship grants DNAPrint the right to place informed-consent kiosks at four Acculab outlets for blood drawing |
| DoubleTwist Inc. | Rigel Pharmaceuticals Inc. (RIGL) | Licensing agreement for DoubleTwist's clustering and alignment tools | The tools allow users to organize volumes of expressed sequence tags and mRNA sequences into full-length gene sequences |
| Genometrix Inc. | GE Medical Systems | Alliance to combine genetic and protein data with diagnostic imaging to enhance early diagnosis and treatment of cancer | The University of Texas M.D. Anderson Cancer Center will pilot the initial research using the combined technologies |
| Genomica Corp. (GNOM) | Celera Genomics Inc. (NYSE:CRA) | Agreement for Genomica to create a "Celera Edition" of its Discovery Manager genetic analysis software suite to integrate with the SNP Reference Database module of the Celera Discovery System | Financial terms were not disclosed |
| Goodwin Biotechnology Inc. | Meristem Therapeutics (France) | Joint cooperative agreement to reinforce Meristem's corn- and tobacco-based production systems in North America | Financial terms were not disclosed |
| Graffinity Pharmaceuticals Inc. | m-phasys GmbH (Germany) | Alliance aimed at G protein-coupled receptor drug discovery platform development and marketing | The platform will include m-phasys' M-FOLD refolding technology for GPCRs and Graffinity's chemical microarray- aided drug discovery technology |
| Hybridon Inc. (OTC BB:HYBN) | EpiGenesis Pharmaceuticals Inc. | Collaboration to develop and market up to five antisense drugs for respiratory diseases | Hybridon will receive a $500,000 up-front cash payment, as well as royalties and sublicense fees |
| IntraBiotics Pharmaceuticals Inc. (IBPI) | Cetek Corp. | Collaboration to identify compounds with antibacterial and antifungal properties using Cetek's capillary electrophoresis screening technology | The agreement is scheduled to last one year with an option to renew |
| Luminex Corp. (LMNX) | ARUP Laboratories | Strategic partnership allowing ARUP to develop and commercialize assays based on Luminex's Multi-Analyte Profiling technology | Luminex will receive a royalty payment from the sales of diagnostic tests developed by ARUP, which will have access to the LabMAP technology |
| Luminex Corp. (LMNX) | Tm Bioscience Corp. (Canada; CDNX:TMC) | Licensing agreement for two key microarray technology components | Luminex obtained rights to Tm's universal tags and hairpin capture probes for applications involving bead-based microarrays; a separate agreement grants Tm rights to develop and market diagnostic products using LabMAP technology |
| Lynx Therapeutics Inc. (LYNX) | GenoMar ASA (Norway) | Collaboration to use Lynx's Megasort technology to identify genes related to saltwater tolerance in the tropical fin fish tilapia | Lynx will receive undisclosed payments from GenoMar for genomics and discovery services
|
| Medarex Inc. (MEDX) and Genmab A/S (Denmark) | Glaucus Proteomics BV (the Netherlands) | Collaboration on an antibody generation deal that could lead to proteomics mapping tools and therapeutic antibodies | The deal is a cost- and profit-sharing arrangement that calls for co-ownership of commercialization rights to the antibodies produced |
| Medarex Inc. (MEDX) | Neuro Therapeutics Inc. | Partnership to develop fully human antibody therapeutics against central nervous system disorders | Medarex will use its UltiMAb platform to produce the therapeutics with Neuro Therapeutics' targets |
| Medarex Inc. (MEDX) | Northwest Biotherapeutics Inc. | Strategic alliance to generate fully human antibodies against cancer | The deal is a cost and revenue sharing arrangement, which includes a $4M equity investment in Northwest; if Northwest goes public in the next year, Medarex will buy an additional $3.5M in common stock |
| MediChem Life Sciences Inc. (MCLS) | Signal Research Division of Celgene Corp. (CELG) | Agreement for the structural determination of a Celgene drug lead bound to a kinase drug target that regulates disease-causing genes | MediChem may receive a bonus payment under the agreement for early completion of project goals |
| MedImmune Inc. (MEDI) | Genaera Corp. (GENR) | Research collaboration and worldwide exclusive licensing agreement to develop and commercialize antibodies or recombinant molecules against interleukin-9 | Agreement could be worth more than $65M in research and development funding, milestone payments, royalties and associated stock purchases to Genaera |
| Miicro Inc. | Duramed Pharmaceuticals Inc. (DRMD) | Agreement to conduct a neuroimaging study to assess the central nervous system effects of Duramed's Cenestin combined with Solvay Pharmaceutical Inc.'s Prometrium | Miicro will conduct the study of Cenestin, a plant-derived estrogen replacement product, and Prometrium, a micronized formulation of progesterone |
| Millennium Pharmaceuticals Inc. (MLNM) | BZL Biologics LLC | Agreement to develop and commercialize antibody-based therapeutics targeting prostate-specific membrane antigen | The companies will work jointly on development programs for immunotoxin and radiolabeled products for prostate cancer through Phase II trials; Millennium then will take responsibility for development, manufacturing and commercialization of therapies for all indications |
| Myriad Genetics Inc. (MYGN) | Hitachi Ltd. (Japan; NYSE:HIT) and Oracle Corp. (ORCL) | Collaboration to map the human proteome in less than three years | Collaboration is worth $185M and will combine Myriad's proteomics expertise with Hitachi's information and electronics technologies and the software capabilities of Oracle |
| Nabi (NABI) | Acambis (ACAM; LSE:ACM) | Agreements for Phase II testing of Acambis' Clostridium difficile toxoid vaccine in plasma donors and the production of specialty plasma to be used in the manufacture of C. difficile immune globulin | Acambis will use Nabi's new manufacturing facility in Boca Raton, Fla., to test and manufacture its product |
| Neogen Corp. (NEOG) | Monsanto Co. | Nonexclusive agreement for access to Monsanto technology | Neogen will use the technology to develop tests for rapid detection of genetically enhanced grains; Neogen also will market the tests |
| Sangamo BioSciences Inc. (SGMO) | Onyx Pharmaceuticals Inc. (ONXX) | Research and development of novel cancer therapeutics using Sangamo's zinc finger DNA-binding protein transcription factor technology platform and Onyx's selectively replicating adenovirus technology | Collaboration could result in the creation of an "armed therapeutic virus" capable of treating disease at the tumor site and systemically |
| SCIL Biomedicals GmbH (Germany) | Biopharm GmbH (Germany) | Partnership to develop a product for the medical regeneration of bone in dental and maxillofacial surgery | Agreement gives SCIL the right to market the jointly owned product worldwide; product will combine MP52 with an appropriate carrier |
| Serono SA (Switzerland; NYSE:SRA; SWX:SEO) | Evotec OAI (Germany; Neuer Markt:EVT) | Services agreement calling for the development of a novel biological assay for a Serono cellular target using Evotec's VliP technology | Evotec will perform screening and compound profiling using its EVO-screen technology to identify chemical compounds that mimic a Serono protein |
| Zyomyx Inc. | Axon Instruments Inc. (ASX:AXN) | Strategic alliance and joint development deal for refining instruments to scan the chips for data gathering and analysis | The companies will develop several generations of scanning products, and evaluate new fluorescence and non-fluorescence imaging platforms |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Abgenix Inc. (ABGX) | Chiron Corp. (CHIR) | Expanded agreement allowing Chiron to use Abgenix's XenoMouse technology to generate fully human monoclonal antibody therapies against multiple cancer-specific antigen targets supplied by Chiron | The first agreement, signed in December 1999, included one antigen in the autoimmune disease field and four cancer antigens; Abgenix will receive milestone and license payments, plus royalties; Chiron will be responsible for product development, manufacturing and commercialization |
| Abgenix Inc. (ABGX) | Diabetogen Biosciences Inc. (Canada) | Collaboration to develop a fully human monoclonal antibody therapy against human antigen CD28 to treat Type I diabetes and other autoimmune diseases | Abgenix will use its XenoMouse technology to generate fully human antibodies against the antigen; Abgenix has an exclusive option to co-develop the product |
| Abgenix Inc. (ABGX) | Impath Inc. (IMPH) | Development and commercialization agreement for antibody therapies for a variety of diseases | Impath will expedite screening of potential targets and Abgenix's XenoMouse-generated product candidates in the field of oncology |
| Arakis Ltd. (UK) | KS Biomedix Holdings plc (UK; LSE:KSB) | Collaboration to develop new arthritis treatments | The collaboration will focus on AD452 and KSB306/7; terms were not disclosed |
| Ashni Naturaceuticals Inc. | Silico Insights Inc. | Collaboration to apply informatics techniques to identify regulatory and post-translational pathways from genomics and proteomics data | Ashni offers its BIOPrinting technology to characterize anti-inflammatory action of mixtures of natural compounds, and Silico will apply its informatics platform to establish dependencies and pathways |
| Bioniche Life Sciences Inc. (Canada; TSE:BNC) | UroCor Inc. (UCOR) | Strategic alliance seeking development and approval for Cystistat | UroCor will have exclusive rights to market and distribute Cystistat; it also will have an option to market Bioniche's mycobacterial cell wall-DNA complex for bladder and prostate cancer in the U.S.; UroCor paid Bioniche an up-front payment of $750,000 and will make additional milestone payments of $2.28M |
| BioSource International Inc. (BIOI) | MiraiBio Inc. | Strategic partnership to create a multiplex system based on LabMAP technology BioSource licensed from Luminex Corp. | MiraiBio will develop software to use with BioSource's assay panels for drug discovery focused on extracellular signaling, neuroscience and signal transduction |
| Celera Genomics Inc. (NYSE:CRA) | Vita Genomics (Taiwan) | Multiyear subscription agreement, giving researchers access to the Celera Discovery System to use Celera's products and systems | Financial terms were not disclosed |
| Cetek Corp. | Genome Therapeutics Corp. (GENE) | Collaboration to develop high-throughput screening assays for identification of drug leads | Cetek will develop capillary electrophoresis assays for validated drug targets and screen the assays against compound libraries |
| EraGen Biosciences Inc. | Genome Therapeutics Corp. (GENE) | Product development and marketing collaboration to deliver EraGen's MasterCatalog with Genome Therapeutics' Pathogenome | No further details were disclosed |
| Gene Logic Inc. (GLGC) | Lark Technologies Inc. (OTC BB:LDNA) | Agreement for Lark to provide genomic services to support Gene Logic's GeneExpress Suite of databases | Lark will be responsible for supporting the CloneExpress Library |
| Genentech Inc. (NYSE:DNA) | Inpharmatica (UK) | Multimillion-dollar, three-year deal that includes a subscription to Inpharmatica's Biopendium proteomics platform | Genentech will take a minority stake in Inpharmatica, as well as pay subscription fees, milestones and potential royalties on a limited number of developed products |
| Genometrix Inc. | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.) | Agreement to identify, characterize and validate single nucleotide polymorphisms | Agouron selected Genometrix to do the work |
| Genometrix Inc. | AniGenics Inc. | Agreement to genotype cattle for single nucleotide polymorphisms associated with parentage confirmation, improved productivity and meat quality | AniGenics will use Genometrix's VistaMorph Genotyping Services and access the VistaLogic Information System for analysis and visualization of the genotyping data |
| Heska Corp. (HSKA) | Genzyme Corp. (GENZ) | Marketing agreement for a product for the detection of Giardia and Cryptosporidium | The agreement gives Heska the right to market the product for use in dogs and cats; financial terms were not disclosed |
| Ilex Oncology Inc. (ILXO) | Bioenvision Inc. (UK) | Agreement to co-develop clofarabine, a nucleoside analogue being developed for hematological malignancies | Ilex plans to develop clofarabine in the U.S. and Canada, where it will have exclusive manufacturing and marketing rights; Ilex will pay $1.1M in an up-front fee, as well as milestone and royalty payments |
| Imaging Research Inc. (Canada) | Biogen Inc. (BGEN) | Collaboration to apply Imaging Research's statistical informatics software, ArrayStat, to Biogen's genome arrays | Collaboration will allow Biogen to analyze its gene expression arrays more rapidly |
| ImmunoGen Inc. (IMGN) | Millennium Pharmaceuticals Inc. (MLNM) | Five-year agreement for Tumor-Activated Prodrug method of delivering cytotoxic agents | Millennium is paying $2M up front and potentially more than $40M in milestone payments per target, as well as royalties; Millennium gains an option for exclusive product licenses in return for a restricted, undisclosed number of antigen targets |
| ImmunoGen Inc. (IMGN) | Raven Biotechnologies Inc. | Collaboration to identify targets and therapeutic antibodies for ovarian cancer | ImmunoGen gets development, manufacturing and commericalization rights in North America and Europe; Raven gets an up-front licensing fee, research support, milestones and royalties |
| Integrative Proteomics Inc. (Canada) | Bruker Daltonics Inc. (BDAL), Burker AXS Inc. and Bruker Instruments Inc. (members of Bruker BioSpin Group) | Strategic alliance focusing on multidisciplinary proteomics technologies based on protein X-ray crystallography, biological NMR and mass spectrometry | Each of the Bruker companies agreed to make an undisclosed equity investment in IPI |
| Introgen Therapeutics Inc. (INGN) | Selective Genetics Inc. | Agreement for process and formulation development | Agreement will supply Selective with clinical-grade manufacturing services for Selective's soft tissue repair gene therapy programs |
| Lynx Therapeutics Inc. (LYNX) | Celera Genomics Inc. (NYSE:CRA) | Agreement for the integration of sets of Lynx's gene expression data into the Celera Discovery System and an agreement for Lynx to apply its MPSS technology to perform additional gene expression analyses for Celera | Financial terms were not disclosed |
| Lynx Therapeutics Inc. (LYNX) | UroGene SA (France) | Collaboration to identify differentially expressed genes with potential therapeutic value against prostate, renal and bladder cancers and prostatic hypertrophy | Lynx will receive undisclosed payments |
| MediGene AG (Germany; Neuer Markt:MDG) | Evotec Biosystems AG (Germany; Neuer Markt:EVT) | Agreement for MediGene to collaborate with Evotec OAI to identify drugs for cardiac diseases | MediGene will keep rights to targets and will receive rights to the identified therapeutic substances; Evotec will receive fixed payments, milestone payments and royalties |
| Meristem Therapeutics Inc. (France) | Quintiles Inc. (QTRN) | Strategic alliance to offer partnering solutions to companies that have discovered proteins of therapeutic benefit that need additional development expertise and resources | Meristem received an equity investment from Quintiles |
| Millennium Pharmaceuticals Inc. (MLNM) | Protein Design Labs Inc. (PDLI) | Agreement giving Millennium options to take commercial licenses for humanized antibodies | Millennium will make an undisclosed signing fee and pay royalties on net sales of resulting products; it can acquire licenses for up to three products for five years |
| Morphochem AG (Germany) | Sosei Co. Ltd. (Japan) | Collaborative research agreement to optimize an anticancer agent | Morphochem will produce libraries of small molecules; the companies will share intellectual property rights resulting from the collaboration |
| Nexell Therapeutics Inc. (NEXL) | Epimmune Inc. (EPMN) | Nonexclusive license agreement for parts of Epimmune's breast, colon and lung epitope package | Nexell will pay an up-front license fee, milestones and royalties; the agreement includes an option for Nexell to acquire nonexclusive rights to another group of cancer antigens |
| Novazyme Pharmaceuticals Inc. | Neose Technologies Inc. (NTEC) | Restructured collaboration in which Neose will relinquish its joint venture right for Novazyme's enzyme replacement therapy for Pompe disease | Neose instead will receive royalty interest for each of Novazyme's drug candidates for lysosomal storage disease, and it will receive cash payments and additional equity in Novazyme |
| November AG (Germany) | ACGT ProGenomics AG (Germany) | Exclusive worldwide rights agreement for a new transfection system that transports nucleic acids into cells | ACGT will receive royalties on sales of the system, which is based on TmHU of a hyperthermophilic bacterium |
| Pharmagene plc (UK; LSE:PGN) | WITA Proteomics AG (Germany) | Collaboration to jointly identify, validate and develop drug targets for partners | Financial details were undisclosed |
| Progenics Pharmaceuticals Inc. (PGNX) and Cytogen Corp. (CYTO) | Abgenix Inc. (ABGX) | Collaboration to use Abgenix's XenoMouse technology to develop antibodies that target prostate-specific membrane antigen | Terms of the collaboration were undisclosed |
| Pyrosequencing AB (Sweden; SSE:PYRO) | Mosaic Technologies Inc. | Cross-license agreement providing access to each other's DNA sequencing technologies | Pyrosequencing gains co-exclusive rights to Mosaic's fluorescent detection technology and Mosaic receives access to Pyrosequencing's sequencing by synthesis technology |
| Ricerca LLC | Cephalon Inc. (CEPH) | Drug development contract to produce Cephalon's angiogenesis inhibitor to treat solid tumors | Ricerca will produce kilogram quantities of the active pharmaceutical ingredient for use in Phase I studies |
| Ricerca LLC; | ICOS Corp. (ICOS) | Agreement to produce a small-molecule inhibitor | The agreement will produce active pharmaceutical ingredient material for use in a Phase I trial |
| Structural Bioinformatics Inc. | ArQule Inc. (ARQL) | Subscription agreement granting ArQule access to SBI's ProMax 3-D drug target protein database | Financial terms were not disclosed |
| Transgenomic Inc. (TBIO) | Synthetic Genetics (division of Epoch Biosciences; EBIO) | Agreement for Synthetic Genetics to use its WAVE System for purification of DNA | Financial details were not disclosed |
| TranXenoGen Inc. | Antitumor Research Products Inc. | Worldwide licensing agreement for human antineoplastic urinary protein | The deal includes a small up-front payment and milestone payments to Antitumor Research Products |
| ViroLogic Inc. (VLGC) | Chiron Corp. (CHIR) | Agreement for ViroLogic to assist Chiron in clinical evaluation of new anti-HIV agents in development | Chiron will use ViroLogic's PhenoSense HIV to evaluate the effectiveness of Chiron's non-nucleoside reverse transcriptase inhibitors |
| Xenogen Corp. | Onyx Pharmaceuticals Inc. (ONXX) | Six-month evaluation license for Xenogen's in vivo imaging technology | Onyx will use the technology to image bioluminescent cancer cells in vivo for its virus research programs |
| Zyomyx Inc. | Dyax Corp. (DYAX) | License agreement for a phage display antibody technology to develop high-density protein biochips using antibodies from Dyax's human antibody library | Zyomyx was granted nonexclusive access to the library for development and worldwide commercialization of protein biochips for research and development activities; terms include research and technology fees, as well as royalties on sales |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Affymetrix Inc. (AFFX) | GeneData AG (Switzerland) | Nonexclusive co-marketing agreement for the GeneData Expressionist software | Affymetrix will promote and recommend Expressionist software for use with its products and software solutions |
| Arena Pharmaceuticals Inc. (ARNA) | Axiom Biotechnologies Inc. | Collaborative research program to develop and share information related to the localization of known G protein-coupled receptors within Axiom's human cell lines | Arena will have exclusive ownership of the information and Axiom's small-molecule data; Arena will purchase a $2M equity stake in Axiom |
| Atrix Laboratories Inc. (ATRX) | MediGene AG (Germany) | European marketing agreement for Atrix's Leuprogel products | Agreement is worth $20M for Atrix, $2M up front, $4M in stock and $14M in milestone payments |
| Aurora Biosciences Corp. (ABSC) | Integrative Proteomics Inc. | Collaboration and license agreement to generate a set of about 3.5M "data points" at Aurora's discovery facility using Integrative's targets | Integrative will license Aurora's high-throughput Big Biology and chemistry platforms and will gain access to a collection of more than 500,000 compounds; Integrative will pay an up-front technology access fee, license fees and support research; Aurora will receive revenues on certain products and will make an equity investment in Integrative |
| Avalon Pharmaceuticals Inc. | Compugen Ltd. (CGEN) | Collaboration to identify and develop drug targets and diagnostic markers through the license of Compugen's Gencarta annotated genome, transcriptome and proteome database and query tools | Compugen will receive cash payments and an equity stake in Avalon; Avalon gets complete rights to develop resulting therapeutic and diagnostic products |
| AVI BioPharma Inc. (AVII) | Exelixis Inc. (EXEL) | Five-year collaboration for antisense drug discovery research and development | AVI will provide its Neugene morpholino antisense agents to Exelixis, and will perform preclinical and clinical studies on antisense drug candidates; candidates will be jointly owned and Exelixis has a codevelopment option |
| Biogen Inc. (BGEN) | Rosetta Inpharmatics Inc. (RSTA) | Licensing agreement for the Rosetta Resolver Gene Expression Data Analysis System | Biogen will use the system in its drug discovery processes |
| Biomax Informatics AG (Germany) | Softberry Inc. | Strategic agreement granting Biomax an exclusive worldwide license to Softberry's complete human genome database | Biomax will develop and annotate the database to create the Pedant Human Genome Database |
| Celltech Group plc (UK; NYSE:CLL) | Evotec OAI (Germany; unit of Evotec BioSystems AG; Neuer Markt:EVT) | Agreement in which Evotec will apply its virus-like particle (VliP) technology to two of Celltech's G protein-coupled receptor targets | Celltech will have the option to obtain a nonexclusive license to use the VliP technology; agreement includes an up-front payment, annual fees and milestone payments |
| Cell Therapeutics Inc. (CTIC) | US Oncology Inc. (USON) | Research services agreement for the execution of up to five clinical studies in colorectal and lung cancers with PG-TXL | Financial details were not disclosed |
| Dendreon Corp. (DNDN) | Covance Biotechnology Services Inc. (subsidiary of Covance Inc.) | Contract agreement to produce antigen used to prepare Provenge for commercial launch | Provenge is Dendreon's prostate cancer vaccine in Phase III trials |
| Diversys Ltd. (UK) | Peptech Ltd. (Australia; ASX:PTD) | Research collaboration agreement to develop single-domain antibody drug candidates against four Peptech targets | Collaboration will generate $10M for Diversys, plus royalties |
| DNAPrint Genomics Inc. (OTC BB:DNAP) | Acculab of South Florida | Agreement to collect and phenotype volunteer blood samples | Relationship grants DNAPrint the right to place informed-consent kiosks at four Acculab outlets for blood drawing |
| DoubleTwist Inc. | Rigel Pharmaceuticals Inc. (RIGL) | Licensing agreement for DoubleTwist's clustering and alignment tools | The tools allow users to organize volumes of expressed sequence tags and mRNA sequences into full-length gene sequences |
| Genometrix Inc. | GE Medical Systems | Alliance to combine genetic and protein data with diagnostic imaging to enhance early diagnosis and treatment of cancer | The University of Texas M.D. Anderson Cancer Center will pilot the initial research using the combined technologies |
| Goodwin Biotechnology Inc. | Meristem Therapeutics (France) | Joint cooperative agreement to reinforce Meristem's corn- and tobacco-based production systems in North America | Financial terms were not disclosed |
| Graffinity Pharmaceuticals Inc. | m-phasys GmbH (Germany) | Alliance aimed at G protein-coupled receptor drug discovery platform development and marketing | The platform will include m-phasys' M-FOLD refolding technology for GPCRs and Graffinity's chemical microarray-aided drug discovery technology |
| Hybridon Inc. (OTC BB:HYBN) | EpiGenesis Pharmaceuticals Inc. | Collaboration to develop and market up to five antisense drugs for respiratory diseases | Hybridon will receive a $500,000 up-front cash payment, as well as royalties and sublicense fees |
| IntraBiotics Pharmaceuticals Inc. (IBPI) | Cetek Corp. | Collaboration to identify compounds with antibacterial and antifungal properties using Cetek's capillary electrophoresis screening technology | The agreement is scheduled to last one year with an option to renew |
| Luminex Corp. (LMNX) | ARUP Laboratories | Strategic partnership allowing ARUP to develop and commercialize assays based on Luminex's Multi-Analyte Profiling technology | Luminex will receive a royalty payment from the sales of diagnostic tests developed by ARUP, which will have access to the LabMAP technology |
| Luminex Corp. (LMNX) | Tm Bioscience Corp. (Canada; CDNX:TMC) | Licensing agreement for two key microarray technology components | Luminex obtained rights to Tm's universal tags and hairpin capture probes for applications involving bead-based microarrays; a separate agreement grants Tm rights to develop and market diagnostic products using LabMAP technology |
| Lynx Therapeutics Inc. (LYNX) | GenoMar ASA (Norway) | Collaboration to use Lynx's Megasort technology to identify genes related to saltwater tolerance in the tropical fin fish tilapia | Lynx will receive undisclosed payments from GenoMar for genomics and discovery services
|
| Medarex Inc. (MEDX) and Genmab A/S (Denmark) | Glaucus Proteomics BV (the Netherlands) | Collaboration on an antibody generation deal that could lead to proteomics mapping tools and therapeutic antibodies | The deal is a cost- and profit-sharing arrangement that calls for co-ownership of commercialization rights to the antibodies produced |
| Medarex Inc. (MEDX) | Neuro Therapeutics Inc. | Partnership to develop fully human antibody therapeutics against central nervous system disorders | Medarex will use its UltiMAb platform to produce the therapeutics with Neuro Therapeutics' targets |
| Medarex Inc. (MEDX) | Northwest Biotherapeutics Inc. | Strategic alliance to generate fully human antibodies against cancer | The deal is a cost and revenue sharing arrangement, which includes a $4M equity investment in Northwest; if Northwest goes public in the next year, Medarex will buy an additional $3.5M in common stock |
| MediChem Life Sciences Inc. (MCLS) | Signal Research Division of Celgene Corp. (CELG) | Agreement for the structural determination of a Celgene drug lead bound to a kinase drug target that regulates disease-causing genes | MediChem may receive a bonus payment under the agreement for early completion of project goals |
| MedImmune Inc. (MEDI) | Genaera Corp. (GENR) | Research collaboration and worldwide exclusive licensing agreement to develop and commercialize antibodies or recombinant molecules against interleukin-9 | Agreement could be worth more than $65M in research and development funding, milestone payments, royalties and associated stock purchases to Genaera |
| Miicro Inc. | Duramed Pharmaceuticals Inc. (DRMD) | Agreement to conduct a neuroimaging study to assess the central nervous system effects of Duramed's Cenestin combined with Solvay Pharmaceutical Inc.'s Prometrium | Miicro will conduct the study of Cenestin, a plant-derived estrogen replacement product, and Prometrium, a micronized formulation of progesterone |
| Millennium Pharmaceuticals Inc. (MLNM) | BZL Biologics LLC | Agreement to develop and commercialize antibody-based therapeutics targeting prostate-specific membrane antigen | The companies will work jointly on development programs for immunotoxin and radiolabeled products for prostate cancer through Phase II trials; Millennium then will take responsibility for development, manufacturing and commercialization of therapies for all indications |
| Myriad Genetics Inc. (MYGN) | Hitachi Ltd. (Japan; NYSE:HIT) and Oracle Corp. (ORCL) | Collaboration to map the human proteome in less than three years | Collaboration is worth $185M and will combine Myriad's proteomics expertise with Hitachi's information and electronics technologies and the software capabilities of Oracle |
| Nabi (NABI) | Acambis (ACAM; LSE:ACM) | Agreements for Phase II testing of Acambis' Clostridium difficile toxoid vaccine in plasma donors and the production of specialty plasma to be used in the manufacture of C. difficile immune globulin | Acambis will use Nabi's new manufacturing facility in Boca Raton, Fla., to test and manufacture its product |
| Neogen Corp. (NEOG) | Monsanto Co. | Nonexclusive agreement for access to Monsanto technology | Neogen will use the technology to develop tests for rapid detection of genetically enhanced grains; Neogen also will market the tests |
| Sangamo BioSciences Inc. (SGMO) | Onyx Pharmaceuticals Inc. (ONXX) | Research and development of novel cancer therapeutics using Sangamo's zinc finger DNA-binding protein transcription factor technology platform and Onyx's selectively replicating adenovirus technology | Collaboration could result in the creation of an "armed therapeutic virus" capable of treating disease at the tumor site and systemically |
| SCIL Biomedicals GmbH (Germany) | Biopharm GmbH (Germany) | Partnership to develop a product for the medical regeneration of bone in dental and maxillofacial surgery | Agreement gives SCIL the right to market the jointly owned product worldwide; product will combine MP52 with an appropriate carrier |
| Serono SA (Switzerland; NYSE:SRA; SWX:SEO) | Evotec OAI (Germany; Neuer Markt:EVT) | Services agreement calling for the development of a novel biological assay for a Serono cellular target using Evotec's VliP technology | Evotec will perform screening and compound profiling using its EVO-screen technology to identify chemical compounds that mimic a Serono protein |
| Zyomyx Inc. | Axon Instruments Inc. (ASX:AXN) | Strategic alliance and joint development deal for refining instruments to scan the chips for data gathering and analysis | The companies will develop several generations of scanning products, and evaluate new fluorescence and non-fluorescence imaging platforms |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Abgenix Inc. (ABGX) | Chiron Corp. (CHIR) | Expanded agreement allowing Chiron to use Abgenix's XenoMouse technology to generate fully human monoclonal antibody therapies against multiple cancer-specific antigen targets supplied by Chiron | The first agreement, signed in December 1999, included one antigen in the autoimmune disease field and four cancer antigens; Abgenix will receive milestone and license payments, plus royalties; Chiron will be responsible for product development, manufacturing and commercialization |
| Abgenix Inc. (ABGX) | Diabetogen Biosciences Inc. (Canada) | Collaboration to develop a fully human monoclonal antibody therapy against human antigen CD28 to treat Type I diabetes and other autoimmune diseases | Abgenix will use its XenoMouse technology to generate fully human antibodies against the antigen; Abgenix has an exclusive option to co-develop the product |
| Abgenix Inc. (ABGX) | Impath Inc. (IMPH) | Development and commercialization agreement for antibody therapies for a variety of diseases | Impath will expedite screening of potential targets and Abgenix's XenoMouse-generated product candidates in the field of oncology |
| Arakis Ltd. (UK) | KS Biomedix Holdings plc (UK; LSE:KSB) | Collaboration to develop new arthritis treatments | The collaboration will focus on AD452 and KSB306/7; terms were not disclosed |
| Ashni Naturaceuticals Inc. | Silico Insights Inc. | Collaboration to apply informatics techniques to identify regulatory and post-translational pathways from genomics and proteomics data | Ashni offers its BIOPrinting technology to characterize anti-inflammatory action of mixtures of natural compounds, and Silico will apply its informatics platform to establish dependencies and pathways |
| Bioniche Life Sciences Inc. (Canada; TSE:BNC) | UroCor Inc. (UCOR) | Strategic alliance seeking development and approval for Cystistat | UroCor will have exclusive rights to market and distribute Cystistat; it also will have an option to market Bioniche's mycobacterial cell wall-DNA complex for bladder and prostate cancer in the U.S.; UroCor paid Bioniche an up-front payment of $750,000 and will make additional milestone payments of $2.28M |
| BioSource International Inc. (BIOI) | MiraiBio Inc. | Strategic partnership to create a multiplex system based on LabMAP technology BioSource licensed from Luminex Corp. | MiraiBio will develop software to use with BioSource's assay panels for drug discovery focused on extracellular signaling, neuroscience and signal transduction |
| Celera Genomics Inc. (NYSE:CRA) | Vita Genomics (Taiwan) | Multiyear subscription agreement, giving researchers access to the Celera Discovery System to use Celera's products and systems | Financial terms were not disclosed |
| Cetek Corp. | Genome Therapeutics Corp. (GENE) | Collaboration to develop high-throughput screening assays for identification of drug leads | Cetek will develop capillary electrophoresis assays for validated drug targets and screen the assays against compound libraries |
| EraGen Biosciences Inc. | Genome Therapeutics Corp. (GENE) | Product development and marketing collaboration to deliver EraGen's MasterCatalog with Genome Therapeutics' Pathogenome | No further details were disclosed |
| Gene Logic Inc. (GLGC) | Lark Technologies Inc. (OTC BB:LDNA) | Agreement for Lark to provide genomic services to support Gene Logic's GeneExpress Suite of databases | Lark will be responsible for supporting the CloneExpress Library |
| Genentech Inc. (NYSE:DNA) | Inpharmatica (UK) | Multimillion-dollar, three-year deal that includes a subscription to Inpharmatica's Biopendium proteomics platform | Genentech will take a minority stake in Inpharmatica, as well as pay subscription fees, milestones and potential royalties on a limited number of developed products |
| Genometrix Inc. | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.) | Agreement to identify, characterize and validate single nucleotide polymorphisms | Agouron selected Genometrix to do the work |
| Genometrix Inc. | AniGenics Inc. | Agreement to genotype cattle for single nucleotide polymorphisms associated with parentage confirmation, improved productivity and meat quality | AniGenics will use Genometrix's VistaMorph Genotyping Services and access the VistaLogic Information System for analysis and visualization of the genotyping data |
| Heska Corp. (HSKA) | Genzyme Corp. (GENZ) | Marketing agreement for a product for the detection of Giardia and Cryptosporidium | The agreement gives Heska the right to market the product for use in dogs and cats; financial terms were not disclosed |
| Ilex Oncology Inc. (ILXO) | Bioenvision Inc. (UK) | Agreement to co-develop clofarabine, a nucleoside analogue being developed for hematological malignancies | Ilex plans to develop clofarabine in the U.S. and Canada, where it will have exclusive manufacturing and marketing rights; Ilex will pay $1.1M in an up-front fee, as well as milestone and royalty payments |
| Imaging Research Inc. (Canada) | Biogen Inc. (BGEN) | Collaboration to apply Imaging Research's statistical informatics software, ArrayStat, to Biogen's genome arrays | Collaboration will allow Biogen to analyze its gene expression arrays more rapidly |
| ImmunoGen Inc. (IMGN) | Millennium Pharmaceuticals Inc. (MLNM) | Five-year agreement for Tumor-Activated Prodrug method of delivering cytotoxic agents | Millennium is paying $2M up front and potentially more than $40M in milestone payments per target, as well as royalties; Millennium gains an option for exclusive product licenses in return for a restricted, undisclosed number of antigen targets |
| ImmunoGen Inc. (IMGN) | Raven Biotechnologies Inc. | Collaboration to identify targets and therapeutic antibodies for ovarian cancer | ImmunoGen gets development, manufacturing and commericalization rights in North America and Europe; Raven gets an up-front licensing fee, research support, milestones and royalties |
| Integrative Proteomics Inc. (Canada) | Bruker Daltonics Inc. (BDAL), Burker AXS Inc. and Bruker Instruments Inc. (members of Bruker BioSpin Group) | Strategic alliance focusing on multidisciplinary proteomics technologies based on protein X-ray crystallography, biological NMR and mass spectrometry | Each of the Bruker companies agreed to make an undisclosed equity investment in IPI |
| Introgen Therapeutics Inc. (INGN) | Selective Genetics Inc. | Agreement for process and formulation development | Agreement will supply Selective with clinical-grade manufacturing services for Selective's soft tissue repair gene therapy programs |
| Lynx Therapeutics Inc. (LYNX) | Celera Genomics Inc. (NYSE:CRA) | Agreement for the integration of sets of Lynx's gene expression data into the Celera Discovery System and an agreement for Lynx to apply its MPSS technology to perform additional gene expression analyses for Celera | Financial terms were not disclosed |
| Lynx Therapeutics Inc. (LYNX) | UroGene SA (France) | Collaboration to identify differentially expressed genes with potential therapeutic value against prostate, renal and bladder cancers and prostatic hypertrophy | Lynx will receive undisclosed payments |
| MediGene AG (Germany; Neuer Markt:MDG) | Evotec Biosystems AG (Germany; Neuer Markt:EVT) | Agreement for MediGene to collaborate with Evotec OAI to identify drugs for cardiac diseases | MediGene will keep rights to targets and will receive rights to the identified therapeutic substances; Evotec will receive fixed payments, milestone payments and royalties |
| Meristem Therapeutics Inc. (France) | Quintiles Inc. (QTRN) | Strategic alliance to offer partnering solutions to companies that have discovered proteins of therapeutic benefit that need additional development expertise and resources | Meristem received an equity investment from Quintiles |
| Millennium Pharmaceuticals Inc. (MLNM) | Protein Design Labs Inc. (PDLI) | Agreement giving Millennium options to take commercial licenses for humanized antibodies | Millennium will make an undisclosed signing fee and pay royalties on net sales of resulting products; it can acquire licenses for up to three products for five years |
| Morphochem AG (Germany) | Sosei Co. Ltd. (Japan) | Collaborative research agreement to optimize an anticancer agent | Morphochem will produce libraries of small molecules; the companies will share intellectual property rights resulting from the collaboration |
| Nexell Therapeutics Inc. (NEXL) | Epimmune Inc. (EPMN) | Nonexclusive license agreement for parts of Epimmune's breast, colon and lung epitope package | Nexell will pay an up-front license fee, milestones and royalties; the agreement includes an option for Nexell to acquire nonexclusive rights to another group of cancer antigens |
| Novazyme Pharmaceuticals Inc. | Neose Technologies Inc. (NTEC) | Restructured collaboration in which Neose will relinquish its joint venture right for Novazyme's enzyme replacement therapy for Pompe disease | Neose instead will receive royalty interest for each of Novazyme's drug candidates for lysosomal storage disease, and it will receive cash payments and additional equity in Novazyme |
| November AG (Germany) | ACGT ProGenomics AG (Germany) | Exclusive worldwide rights agreement for a new transfection system that transports nucleic acids into cells | ACGT will receive royalties on sales of the system, which is based on TmHU of a hyperthermophilic bacterium |
| Pharmagene plc (UK; LSE:PGN) | WITA Proteomics AG (Germany) | Collaboration to jointly identify, validate and develop drug targets for partners | Financial details were undisclosed |
| Progenics Pharmaceuticals Inc. (PGNX) and Cytogen Corp. (CYTO) | Abgenix Inc. (ABGX) | Collaboration to use Abgenix's XenoMouse technology to develop antibodies that target prostate-specific membrane antigen | Terms of the collaboration were undisclosed |
| Pyrosequencing AB (Sweden; SSE:PYRO) | Mosaic Technologies Inc. | Cross-license agreement providing access to each other's DNA sequencing technologies | Pyrosequencing gains co-exclusive rights to Mosaic's fluorescent detection technology and Mosaic receives access to Pyrosequencing's sequencing by synthesis technology |
| Ricerca LLC | Cephalon Inc. (CEPH) | Drug development contract to produce Cephalon's angiogenesis inhibitor to treat solid tumors | Ricerca will produce kilogram quantities of the active pharmaceutical ingredient for use in Phase I studies |
| Ricerca LLC; | ICOS Corp. (ICOS) | Agreement to produce a small-molecule inhibitor | The agreement will produce active pharmaceutical ingredient material for use in a Phase I trial |
| Structural Bioinformatics Inc. | ArQule Inc. (ARQL) | Subscription agreement granting ArQule access to SBI's ProMax 3-D drug target protein database | Financial terms were not disclosed |
| Transgenomic Inc. (TBIO) | Synthetic Genetics (division of Epoch Biosciences; EBIO) | Agreement for Synthetic Genetics to use its WAVE System for purification of DNA | Financial details were not disclosed |
| TranXenoGen Inc. | Antitumor Research Products Inc. | Worldwide licensing agreement for human antineoplastic urinary protein | The deal includes a small up-front payment and milestone payments to Antitumor Research Products |
| ViroLogic Inc. (VLGC) | Chiron Corp. (CHIR) | Agreement for ViroLogic to assist Chiron in clinical evaluation of new anti-HIV agents in development | Chiron will use ViroLogic's PhenoSense HIV to evaluate the effectiveness of Chiron's non-nucleoside reverse transcriptase inhibitors |
| Xenogen Corp. | Onyx Pharmaceuticals Inc. (ONXX) | Six-month evaluation license for Xenogen's in vivo imaging technology | Onyx will use the technology to image bioluminescent cancer cells in vivo for its virus research programs |
| Zyomyx Inc. | Dyax Corp. (DYAX) | License agreement for a phage display antibody technology to develop high-density protein biochips using antibodies from Dyax's human antibody library | Zyomyx was granted nonexclusive access to the library for development and worldwide commercialization of protein biochips for research and development activities; terms include research and technology fees, as well as royalties on sales |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| Abgenix Inc. (ABGX) | Celltech Group plc | Licensing agreement for the SLAM (Selected Lymphocyte Antibody Method) technology | Abgenix will receive a $17M up-front payment in Celltech shares, plus royalties |
| Ambion Inc. | Qiagen Inc. (the Netherlands; QGENF) | Collaboration granting Qiagen nonexclusive worldwide rights to Ambion's RNAlater RNA stabilization technology | Financial terms were undisclosed |
| atugen AG (Germany) | G.O.T. Therapeutics GmbH (Germany) | Agreement to develop new lipid formulations for enhanced intracellular delivery of atugen's GeneBloc molecules | The companies will share all costs and intellectual property equally, and G.O.T. will retain exclusive use of resultant products in DNA therapy |
| Biovation Ltd. (UK) | Epicyte Pharmaceutical Inc. | Research agreement to optimize antibodies for development through Epicyte's Plantibody technology | Biovation will earn research revenues, milestones and royalties |
| Boston Probes Inc. | Gene Therapy Systems Inc. | Five-year, nonexclusive license for the sale of its GeneGrip life science research products that incorporate PNA technology | Gene Therapy will pay an up-front fee, annual royalties, as well as earned royalties from product sales |
| CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Cangene Corp. (Canada; TSE:CNJ) | Agreement to develop a slow-release formulation of an unnamed protein drug | CeNeS will apply its Depocore technology to reduce 30-fold the frequency with which the Cangene drug must be injected; CeNeS receives an initial fee, will manufacture the product and will receive royalties |
| Chiron Corp. (CHIR) | AcroMetrix Inc. | Agreement for a worldwide, semi-exclusive license, including blood screening, allowing AcroMetrix to develop, research, manufacture and sell HCV and HIV nucleic acid probe quality controls, standards and quantification panels for in vivo diagnostics | Chiron will receive an up-front license fee, milestone payments and royalties |
| Chiron Corp. (CHIR) | Zarix Inc. | Agreement giving Zarix exclusive worldwide rights to recombinant human macrophage-colony stimulating factor to treat cancer and infectious disease | Zarix gains the right to make, develop and commercialize rM-CSF; Chiron will receive an up-front license fee, milestone payments and royalties |
| Cognia Corp. | Biobase GmbH (Germany) | Alliance between Cognia and Biobase, as well as Harvard Medical School | The deal grants researchers access to Cognia and Biobase bioinformatics products |
| Commonwealth Biotechnologies Inc. (CBTE) | november AG (Germany) | Research and development joint venture agreement to develop new methods for the detection of microbial contamination in a variety of areas, including water and soil | The joint venture will use november's electrohybridization technology |
| Crucell NV (the Netherlands; CRXL) | DirectGene Inc. | Production agreement to manufacture DirectGene's product to treat prostate cancer | Crucell will use its human cell line production platform, PER.C6 in the manufacturing agreement |
| Gene Logic Inc. (GLGC) | Genentech Inc. (NYSE:DNA) | Subscription agreement giving Genentech access to the BioExpress Module of Gene Logic's GeneExpress Suite | Financial terms of the multiyear subscription were not disclosed |
| Genetix Group plc (UK; LSE:GTX.L) | Pall Corp. (NYSE:PLL) | Strategic alliance to develop and commercialize novel membranes | Membranes will optimize robotic high-density array printing and detection methods for DNA and proteins |
| Genicon Sciences Corp. | Pall Corp. (NYSE:PLL) | Agreement to apply Pall's membrane technology and Genicon's RLS technology to develop an enhanced system for labeling, detection and study of biological analytes | Terms of the agreement were not disclosed |
| GenomicFX LP | Incyte Genomics Inc. (INCY) | Partnership calling for GenomicFX to use Incyte's gene databases and custom genomics services to develop advanced genetic information tools for use in improving meat quality, food safety and livestock production efficiency | GenomicFX will get access to Incyte's LifeSeq Gold and Zooseq databases in addition to custom services enabling it to create database resources for cattle and swine |
| Genzyme Transgenics Corp. (GZTC) | Atlantic BioPharmaceuticals Inc. | Agreement to produce ABI.001 | Genzyme will produce transgenic goats that express the protein in their milk |
| Gryphon Sciences Inc. | Geneva Proteomics Inc. | Collaboration for chemical synthesis of proteins identified by proteomic analysis | Geneva Proteomics will manufacture proteins using Gryphon's chemical protein synthesis technologies |
| HTS Biosystems Inc. | Dyax Corp. (DYAX) | Nonexclusive license exchange agreement under which Dyax receives premarket access to a grating-coupled surface plasmon resonance array system | Dyax will grant HTS a patent license to use its phage display technology; in return, Dyax will receive royalties on sales |
| Idun Pharmaceuticals Inc. | Selective Genetics Inc. | License agreement for the use of Idun's Bcl-2 gene | Selective Genetics will use the gene in conjunction with its delivery technologies for the development of gene therapy products for tissue repair and regeneration |
| Imgenex Corp. | Genzyme Molecular Oncology (GZMO) | Alliance aimed at reagent development useful in the study of angiogenesis | Imgenex will develop monoclonal antibodies that recognize and potentially interfere with the function of proteins discovered and characterized by the two companies |
| Incyte Genomics Inc. (INCY) | Genicon Sciences Corp. | Development collaboration for resources to detect infinitesimal levels of proteins present in biological samples | Incyte receives certain rights to codevelop and commercialize Genicon's RLS technology with Incyte array products |
| Inflazyme Pharmaceuticals Ltd. (TSE:IZP) | Helicon Therapeutics Inc. | Research agreement to examine the potential of small-molecule anti-inflammatory compounds in the learning and memory fields | Helicon will take care of preclinical costs and will make milestone payments and pay royalties; it will have the right to license a compound for development |
| IntraBiotics Pharmaceuticals Inc. (IBPI) | Albany Molecular Research Inc. (AMRI) | Research and technology licensing agreement for the discovery and development of anti-infective therapies | Two-year renewable agreement in which AMRI will receive technology access fees, research funding, milestone and royalty payments; IntraBiotics gains exclusive worldwide rights |
| KS Biomedix Holding plc (UK) | Aurelium BioPharma Inc. (Canada) | Research and development collaboration that calls for KS to develop super-high-affinity antibodies for Aurelium protein targets expressed on tumor cells that are resistant to anticancer drugs | The companies initially will focus on blood cancers |
| Large Scale Biology Corp. (LSBC) | ProdiGene Inc. | Collaborative alliance for the development and large-scale manufacture of therapeutic antibodies | Alliance will focus on the commercialization of proteins produced in plants |
| Lexicon Genetics Inc. (LEXG) | Immunex Corp. (IMNX) | Multiyear, nonexclusive sublicense for the use of gene targeting technology for Immunex internal research | Lexicon will receive annual license fees, technology usage fees and milestone payments |
| Medarex Inc. (MEDX) | Biosite Diagnostics Inc. (BSTE) and Eos Biotechnology Inc. | Three-way collaboration aimed at using Eos targets to create anticancer antibodies using Medarex and Biosite's Transphage technology | Eos will provide Biosite targets over three years, as well as development, milestone, maintenance and royalty fees; Biosite will get diagnostic rights to the targets, and Medarex expects to receive payment for those rights, pursuant to its 1999 collaboration with Eos |
| Medarex Inc. (MEDX) | Immusol Inc. | Strategic alliance for the development of fully human antibody therapeutics | Agreement calls for equal cost-sharing responsibility for development and commercialization of potential therapeutics developed with UltiMAb Human Antibody Development System to Immusol targets |
| Medarex Inc. (MEDX) | Seattle Genetics Inc. | Strategic alliance to use Medarex's UltiMAb Human Antibody Development System to jointly develop and commercialize monoclonal antibody-based anticancer therapeutics | Companies will share development costs and jointly commercialize any resulting products |
| MedImmune Inc. (MEDI) | Targesome Inc. | Agreement to study the potential of combining MedImmune's anti-angiogenesis product, Vitaxin, with Targesome's nanoparticle technology | MedImmune will assume responsibility for Phase II trials and subsequent development, manufacturing and marketing; it has made a $1.5M equity investment in Targesome and will make milestone payments and royalty payments on potential sales |
| MWG-Biotech AG (Germany) | Affymetrix Inc. (AFFX) | Modified distribution agreement for the sale of Affymetrix's spotted array instrumentation in Europe, North America and South America | MWG-Biotech will now offer the instrumentation in combination with its existing array and reagent product offerings |
| Peregrine Pharmaceuticals Inc. (PPHM) | SuperGen Inc. (SUPG) | Vascular Targeting Agent technology licensing agreement | Deal is potentially worth $8M, consisting of an up-front equity investment and milestone payments, as well as royalties |
| PPD Discovery (unit of PPD Inc.; PPDI) | InforMax Inc. (INMX) | Technology access agreement to use the GenoMax enterprise bioinformatics system | PPD gains broad access to the system to manage and analyze genomic data |
| PPD Discovery (subsidiary of PPD Inc.; PPDI) | Affymetrix Inc. (AFFX) | BiotechAccess agreement | Agreement gives PPD access to Affymetrix's GeneChip arrays, instrumentation and software to monitor gene expression |
| Questcor Pharmaceuticals Inc. (AMEX:QSC) | Tularik Inc. (TLRK) | Licensing agreement for certain antifungal drug research technology | The license is in exchange for a cash payment and future potential milestone and royalty payments |
| Rosetta Inpharmatics Inc. (RSTA) | Immunex Corp. (IMNX) | Licensing agreement for the Rosetta Resolver Expression Data Analysis System | Immunex will use the system for high-capacity data storage, retrieval and analysis of expression data |
| SYN X Pharma Inc. (Canada) | genOway SA (France) | Collaboration to combine expertise in proteomics and genomics to develop cardiovascular and central nervous system drug targets | SYN X and genOway will test products through Phase I trials, and then will license the products to pharmaceutical companies; the companies will share revenues |
| The Generics Group (UK; LSE:GEN) and BTG International Inc. (UK; LSE:BGC) | Aura Oncology Systems Inc. | Licensing agreement for a patent portfolio in electronics and the life sciences | License could lead to a bio-chip technology that could assist in cancer diagnosis and oncologics development |
| Xenerex Biosciences (subsidiary of Avanir Pharmaceuticals Inc.; AMEX:AVN) | IDEC Pharmaceuticals Corp. (IDPH) | Agreement giving Xenerex patent rights to U.S. patent No. 5,958,765 for the generation of fully human monoclonal antibodies using human spleen cells grafted into severe combined immunodeficient mice | IDEC will receive a 5% ownership interest in Xenerex and royalties on sales resulting from the use of the patent |
| Zyogen LLC | Curis Inc. (CRIS) | Agreement providing limited access to Curis of transgenic zebrafish technology | Zyogen 's technology, Z-tag, will be used by Curis in its drug discovery program |
| |
|||
| Company | Company | Type/Product Area | Terms/Details |
| 3-Dimensional Pharmaceuticals Inc. (DDDP) | Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ) | Agreement for worldwide rights to 3DP's orally active direct thrombin inhibitor program, 3DP-4815 | 3DP will receive an up-front cash payment of $6M and further milestone payments of up to $44M; Centocor will be responsible for development and worldwide commercialization of all compounds under the agreement |
| Abgenix Inc. (ABGX) | Amgen Inc. (AMGN) | Extended research collaboration calling for Abgenix to use its XenoMouse technology to generate fully human monoclonal antibodies to antigen targets provided by Amgen over the five-year term | Original agreement began in April 1999 |
| Affymetrix Inc. (AFFX) | Genomic Solutions Inc. (GNSL) | License agreement for commercialization rights to low- and medium-density DNA arrays | Genomic Solutions receives a nonexclusive, worldwide, royalty-bearing license and Affymetrix receives an undisclosed up-front fee and royalties on sold arrays |
| Affymetrix Inc. (AFFX) | Lexicon Genetics Inc. (LEXG) | BiotechAccess agreement giving Lexicon broad access to Affymetrix's GeneChip arrays, instrumentation and software | Lexicon will use the technology to monitor gene expression and to share phenotypic and expression analysis information on new and existing targets |
| Altus Biologics Inc. | Triangle Pharmaceuticals Inc. (VIRS) | Research agreement to develop biocatalytic processes for use in the synthesis of compounds in Triangle's drug development pipeline | Altus will receive funding in return for specific worldwide commercialization rights |
| Applied Biosystems Group (NYSE:ABI) | Agilent Technologies Inc. (NYSE:A) | Technology access agreement for Agilent to supply custom in situ synthesized oligonucleotide microarrays to Applied Biosystems | The agreement does not cover commercialization of the Agilent microarrays |
| Aurora Biosciences Corp. (ABSC) | Deltagen Inc. (DGEN) | Nonexclusive license agreement for Aurora's gene fluorescent protein technology in the U.S. | Deltagen will make certain license fee payments and it has the option to expand its use of the technology upon additional payments |
| Aurora Bioscience Corp. (ABSC) | Allergan Inc. (NYSE:AGN) | Agreement is for ion channel drug discovery for ophthalmic indications | Includes an up-front payment to Aurora and additional milestone payments and royalties |
| Avalon Pharmaceuticals Inc. | ImmunoGen Inc. (IMGN) | License agreement to develop antibody-based products based on genomic targets | Avalon will receive milestone payments in agreement focused on cancer |
| AviGenics Inc. | Demegen Inc. (OTC BB:DBOT) | Expanded research and development collaboration to develop disease-resistant poultry | AviGenics gains an exclusive worldwide license for Demegen's antimicrobial peptide library and an additional license for Demegen's technologies for transgenic poultry creation |
| Caliper Technologies Inc. (CALP) | Structural GenomiX | Joint development collaboration focused on high-throughput protein analysis with Caliper's Automated Microfluidics System 90 platform | Financial terms were not disclosed |
| Celera Genomics Inc. (NYSE:CRA) | Genset SA (France; GENXY) | Multiyear subscription agreement granting Genset access to Celera's databases | Terms were not disclosed |
| Cerep SA (France) | Laboratoires Fournier (France), Grunenthal (Germany), Zambon (Italy) and a fourth anonymous company | Collaboration agreements for the creation of libraries of therapeutic compounds | Each agreement is for two years; each library will be paid for separately with the four companies paying equal amounts |
| COR Therapeutics Inc. (CORR) and Schering-Plough Corp. | Genentech Inc. (NYSE:DNA) | Copromotion agreement for Integrilin | Genentech will copromote Integrilin and Cor and Schering-Plough will copromote TNKase and Activase |
| Crucell NV (the Netherlands; CRXL) | Cell Genesys Inc. (CEGE) | Licensing agreement for access to Crucell's PER.C6 technology | Cell Genesys has a license with an option to convert it to a commercial license within five years |
| Cubist Pharmaceuticals Inc. (CBST) | Gilead Sciences Inc. (GILD) | Licensing agreement to market Cidecin and an oral formulation of daptomycin overseas | Deal worth $44M includes an up-front licensing fee of $13M for Cubist, as well as additional payments of up to $31M in milestones, plus royalties |
| Curis Inc. (CRIS) | Aegera Therapeutics Inc. | Licensing and research agreement granting Curis exclusive worldwide rights to skin-derived adult stem cell technologies | The deal is valued at more than $25M |
| DNA Sciences Inc. | Amersham Pharmacia Biotech Inc. (unit of Nycomed Amersham plc; NYSE:NYE; LSE:NAM) | Collaboration to develop microchannel chip technology for automated high-throughput analysis of nucleic acids | Amersham will pay DNA Sciences licensing fees and royalties from future product sales |
| DoubleTwist Inc. | Genomatix Software GmbH (Germany) | Partnership aimed at aiding scientific gene characterization | The collaboration will merge Doubletwist's Annotated Human Genome Database with Genomatix's Promoter Resource database for the molecular switches that regulate gene expression analysis |
| Dyax Corp. (DYAX) | Abgenix Inc. (ABGX) | Collaboration to develop new technologies for discovering and developing human antibody therapeutics | Companies will share costs and each will pay reciprocal commercialization fees |
| Dyax Corp. (DYAX) | Human Genome Sciences Inc. (HGSI) | Exclusive licensing agreement to purify HGS' B-lymphocyte stimulator protein, BLyS | HGS received a protein purification license to a family of Dyax's custom peptide ligands; Dyax received a license fee and will receive commercial milestone payments, as well as royalties |
| Gene Logic Inc. (GLGC) | Idec Pharmaceuticals Inc. (IDPH) | Agreement granting Idec a subscription to the Gene Express Oncology Data Suite for use in drug discovery programs | Financial terms were not disclosed |
| Genescan Europe AG (Germany) | Clinical Micro Sensors (unit of Motorola Inc.; NYSE:MOT) | Collaboration to develop and deliver new DNA detection tools aimed at identifying genetically modified crops | Alliance will use Motorola's eSensor DNA detection system |
| GeneTrace Systems Inc. | Molecular Mining Corp. (Canada) | Collaboration to design, analyze, define and validate a physiological network model for application in drug discovery | The companies will co-fund the research and share the revenues generated by any findings |
| Genometrix Inc. | VistaGen Inc. | Collaboration to combine in vitro stem cell biology with high-throughput microarrays to discover surrogate markers for predictive toxicology screening for drug development | Collaboration will focus on identifying drug-responsive genes |
| Genomics Collaborative Inc. | NetGenics Inc. | Joint development collaboration to create and develop the first application of the genotypic DataMart | Companies will apply the DataMart to analysis and mining of annotated, genotypic data |
| Genzyme Transgenic Corp. (GZTC) | Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ) | Expanded agreement to include a worldwide semi-exclusive license for commercial production of tumor necrosis factor antagonists | Agreement calls for a license fee payment to Genzyme of $4M |
| Geron Corp. (GERN) | Clone Australia Pty. Ltd. | Licensing agreement for access to Geron's nuclear transfer technology to produce superior cattle and sheep for agricultural applications in Australia, New Zealand and China | Geron will receive equity in Clone Australia in addition to a share of revenues |
| Icogen Corp. | HemeBiotech A/S (Sweden) | Agreement to develop a cell-based system for the production of a therapeutic protein | No further details were disclosed |
| Incyte Genomics Inc. (INCY) | Agilent Technologies Inc. (NYSE:A) | Licensing agreement for development and commercialization of gene expression arrays | Agilent gains access to Incyte cDNA clones to develop human and animal microarrays |
| Incyte Genomics Inc. (INCY) | Oxagen Ltd. (UK) | Collaborative research agreement to investigate the genetics of osteoporosis | The collaboration pairs Incyte's LifeSeq Gold database of genetic sequences with Oxagen's Family Osteoporosis sample collection and database; financial terms were not disclosed |
| Incyte Genomics Inc. (INCY) | Senomyx Inc. | Licensing agreement for Incyte's gene sequence database to discover genes involved in taste, olfaction and the detection of pheromones | Under specific situations Senomyx will have the ability to take exclusive licenses to gene patents that relate to commercialization of flavor and fragrance products |
| InforMax Inc. (INMX) | Biomax Informatics AG (Germany) | Agreement to grant InforMax exclusive worldwide distribution rights to the BioRS Integration and Retrieval System developed by Biomax | Four-year agreement in which the companies will integrate BioRS's capabilities with the InforMax platform, and InforMax will market solutions using the combined technologies |
| IntraBiotics Pharmaceuticals Inc. (IBPI) | Diversa Corp. (DVSA) | Agreement to identify and develop small-molecule compounds with antibacterial or antifungal properties, derived from Diversa's libraries | Diversa gets access fees, research fees and milestone payments; IntraBiotics gets an exclusive worldwide license to resulting products; deal is worth $20M |
| Large Scale Biology Corp. (LSBC) | Biosite Diagnostics Inc. (BSTE) | Technology alliance to generate antibody and protein target components for protein biochips | Large Scale expects to provide 2,000 to 5,000 protein targets, as well as expressed proteins produced with its Geneware technology; Biosite will use its high-throughput Omniclonal phage-display technology to generate antibodies to the targets |
| Lexicon Genetics Inc. (LEXG) | Abgenix Inc. (ABGX) | Multiyear agreement under which Lexicon will validate monoclonal antibody targets for Abgenix | Lexicon will use its mammalian assays to determine a gene sequence's function in a mammalian system |
| Lynx Therapeutics Inc. (LYNX) | Phytera Inc. | Collaboration to identify plant genes involved in the biosynthesis of antioxidant polyphenols | The companies will validate gene targets and will jointly commercialize the genes with other partners |
| MDS Proteomics Inc. (Canada; unit of MDS Inc.; NYSE:MDZ; TSE:MDS) | IBM (IBM) | Strategic alliance to establish a public research database and to conduct research projects | IBM will supply hardware, software and services and will make an equity investment in MDS |
| Medarex Inc. (MEDX) | B. Twelve Inc. (Canada) | Research, development and commercialization agreement for cancer therapeutics using Medarex's UltiMAb Human Antibody Development System and B. Twelve's targeted technology | Medarex expects to receive license fees and milestone payments, as well as royalties; it has received 9% of B. Twelve's outstanding stock |
| Medarex Inc. (MEDX) | Novo Nordisk A/S (Denmark; NYSE:NVO) | Alliance to develop fully human antibody therapeutics | Alliance will combine Medarex's UltiMAb Human Antibody Development System and T-12 Development with Novo Nordisk's fusion protein expertise; Novo Nordisk will develop and commercialize any resulting products and Medarex will receive up-front payments, as well as milestones and royalties |
| Micralyne Inc. (Canada) | MDS Sciex (division of MDS Inc.; Canada) | Multiyear agreement to jointly develop microfluidic technology for use in drug discovery instrumentation | Micralyne will license existing microfluidic technology and develop new technology for use in frontal affinity chromatography |
| MorphoSys AG (Germany; Neuer Markt:MOR) | Biogen Inc. (BGEN) | Collaboration to apply MorphoSys' Human Combinatorial Antibody Library antibody-generation technology for expressed sequence tags to efforts to validate drug targets | Biogen receives an option to develop selected antibodies, and will pay research costs, an undisclosed up-front technology access fee and milestone and royalty payments |
| MorphoSys AG (Germany; Neuer Markt:MOR) | Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ) | Technology license agreement granting Centocor access to MorphoSys' HuCAL technology for antibody generation | Deal is worth US$20.71M; MorphoSys also will receive royalty payments on any commercialized drugs |
| Orchid BioSciences Inc. (ORCH) | Exelixis Inc. (EXEL) | Collaboration for access to Orchid's SNPcode | Financial terms were not disclosed |
| OSI Pharmaceuticals Inc. (OSIP) | Genentech Inc. (NYSE:DNA) and Roche Holdings Inc. | Agreement to codevelop and commercialize OSI-774 for cancers | Roche and Genentech each will buy $35M worth of OSI stock, along with paying up-front fees; agreement is potentially worth $187M |
| Oxagen Ltd. (UK) | Amersham Pharmacia Biotech Inc. (unit of Nycomed Amersham plc; NYSE:NYE; LSE:NAM) | Agreement for the SniPer high-throughput single nucleotide polymorphism genotyping technology platform | Oxagen acquired access to SniPer for a minimum of three years |
| Pantheco A/S (Denmark) | Zydus Cadila (India) | Research and development agreement for antibacterials | Each company will fund its own research effort, and profits will be shared equally |
| Phogen Ltd. (UK) | atugen AG (Germany) | Collaboration to evaluate Phogen's VP22 Vectosome technology for the intracellular delivery of atugen's GeneBloc molecules for applications in functional genomics | atugen also has an option to take a license for the technology for use in target validation screens |
| Protogene Laboratories Inc. | Sequenom Inc. (SQNM) | Collaboration to develop novel single nucleotide polymorphism analysis tools for use with Sequenom's MassArray system | The collaboration will integrate DNA microarray technology with the MassArray system |
| Qiagen Genomics Inc. (QGENF) | Agilent Technologies Inc. (NYSE:A) | Reseller and copromotion agreement for companies to develop SNP genotyping systems | Qiagen will market the systems; companies will jointly develop Masscode tag chemistry and mass spectrometry instrumentation solutions for SNP discovery |
| Qiagen Genomics Inc. (QGENF) | Genomics Collaborative Inc. | Collaboration to analyze genetic profiles | Companies will focus on profiles of geographically distinct patient populations with known poor drug metabolism vs. an equal set of control patients |
| Sangamo BioSciences Inc. (SGMO) | Renessen LLC (joint venture between Cargill and Monsanto Co.; NYSE:MON) | Agreement to apply Sangamo's gene regulation technology to enhance the value of certain crops for the animal feed and processing industries | Sangamo will receive certain payments, research funding and royalties; Renessen gets a worldwide exclusive license |
| Scios Inc. (SCIO) | Quintiles Transnational Corp. (QTRN) | Commercialization agreement for Natrecor to treat congestive heart failure | Quintiles subsidiary Innovex Inc. will provide a 180-person sales force, for which Quintiles expects about a $100M consideration through a net sales royalty stream over three-and-a-half years; Quintiles will foot a $35M commercialization tab through its corporate ventures group, PharmaBio Development |
| Theratechnologies Inc. (Canada; TSE:TH) | BioArtificial Gel Technologies (Canada) | License agreement extension for the extraction processes and the applications of Theratechnologies' platelet-derived growth factor cocktail | The new license agreement covers the in vivo use for therapeutic purposes in the areas of tissue engineering and wound healing |
| Union Biometrica Inc. | Clontech Laboratories Inc. | Licensing agreement for COPAS technology platform for automated drug testing in model organisms | Financial details were unavailable |
| Variagenics Inc. (VGNX) | Amgen Inc. (AMGN) | Agreement to apply Variagenics' Variagenic Impact Program to the development of an Amgen therapeutic | Financial details were not disclosed
|
| Versicor Inc. (VERS) | Biosearch Italia SpA (Italy; Nuovo Mercato:BIO) | Expanded development partnership in anti-infective product leads | Expansion calls for formation of a research team; Biosearch will contribute additional selected microbial library compounds, fermentation extracts and high-throughput screening beyond the scope of the original agreement; Versicor will provide additional selected targets and assays for screening purposes |
| Xenogen Corp. | Chiron Corp. (CHIR) | Evaluation license allowing Chiron access to Xenogen's real-time in vivo imaging technologies | Chiron will evaluate the technology for drug discovery applications in the treatment of cancer |
| XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL) | Dyax Corp. (DYAX) | Collaborative agreement to discover, develop and commercialize fully human monoclonal antibodies to treat and/or prevent selected fungal infections and to treat selected cancers | The companies will share equally all development funding and any outlicensing or other revenues |